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Abstract 
Rapid, Large-Scale Production of Full-Length, 
Human-Like Monoclonal Antibodies 
 
By 
 
Christopher M Warner 
Keck Graduate Institute of Applied Life Sciences 2012 
 
 Current recombinant protein production systems require several months to develop. 
Existing systems fail to provide timely, flexible, and cost-effective therapies to protect against 
emergency mass-casualty infections or poisonings. As the identity of many new biological 
threat agents are unlikely to be known in advance, pre-emptive manufacturing and stockpiling 
of countermeasures cannot be performed.  Preparedness for a biological catastrophe requires a 
radical solution to replace the current slow scale-up and manufacture of lifesaving medical 
countermeasures. Subunit vaccines and antibody fragments may be produced in bacteria, 
yeast, plant or insect cells. However, generation of full-length, human like glycosylated 
antibodies requires mammalian cell culture due to the cell’s ability to carry out complex 
assembly and processing. Although commercial cell culture methods for antibody production 
from stable gene expression have been substantially improved over the last 30 years, the time 
required to achieve full scale production for a new product is too long for a rapid, emergency 
response. An alternative method for rapid production of high quality antibody protein is 
transient gene expression. 
 Transient gene expression is an established, routine approach to small scale, research-
grade material of recombinant proteins.  It is frequently used to generate gram quantities of 
material within weeks of lead target identification. In the past, transient gene expression has 
been considered for emergency production of large production of antibodies, but dismissed 
due to low titers, high DNA requirements, uncertain regulations, unavailable manufacturing 
capacity, and uncertain scale-up performance. If these barriers can be overcome in the next 
few years, emergency use of transient gene expression for production of life saving medical 
countermeasures would be a viable means to help protect our nation from biological attacks.  
 The goal of this thesis is to investigate both the technical and operational feasibility of 
scaling up transient gene expression. In order to investigate the technical feasibility of such a 
method, a phenomenological understanding of transfection was developed for process 
characterization, process optimization and scale-up studies. Experiments in shaker flasks and 
lab-scale bioreactors interrogated a number of factors involved in the transfection process and 
identified an optimal design space for performing transfections (Chapters 2 and 3). Important 
factors that were identified include cell/DNA/PEI ratio, transfection incubation time, and 
agitation set points. Through this optimization process, the highest reported titer (>300 mg/L) 
in transient CHO production was achieved.  
 Experimental transfections also provided calibration metrics for phenomenological 
models of mass transfer in very large bioreactors. These models were used to investigate the 
potential of mass transfer limitations upon scale-up (Chapter 2). The results indicate that, with 
appropriate design of the agitation systems, including consideration of the impact of mass 
transfer of PEI/DNA complexes from the medium to the cells during the transfection stage, 
scale-up should be successful.  In the final stage of experimentation, successful identification of 
scalable systems for aseptic liquid-cell separation eliminated other potential bottlenecks that 
may be encountered during scale-up (Chapter 3).  A novel combination of existing technology 
generated simplified transfection protocols, which may be commercialized for alternative 
markets.  
 Operational feasibility was investigated through a survey of current manufacturing 
capacity for mammalian cell culture and their capabilities to provide meaningful emergency 
production of antibody countermeasures.  Process simulation was conducted to analyze 
process flow, plant design, and cost for large scale production of both plasmid DNA (Chapter 5), 
a sub-component of transient gene expression, as well as antibody protein (Chapter 4). 
Simulations predicted that a 1,000-L fermentor would produce sufficient plasmid DNA at a cost 
of approximately $377/gram.  This DNA could be utilized in a 200,000-L facility to produce 
between 32 and 1,274 kg of recombinant antibody. Experimentally validated transfection 
processes were then used to refine simulations. Subsequent simulation resulted in production 
of 197 kg within 3 months at a cost of 705 $/gram mAb.  These simulations predict that large-
scale transient gene expression can provide sufficient lifesaving countermeasures if titer 
improvements are possible and can be successfully scaled to large bioreactors. 
 This thesis demonstrates both the operational and technical feasibility of a successful 
large-scale transient gene expression platform for the production of full-length, human-like 
glycosylated antibodies as medical countermeasures for biological catastrophe. This approach is 
one critical component of our Nation’s arsenal of bio-defense capabilities.  
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CHAPTER 1. ACCELERATED MANUFACTURING OF LARGE-
SCALE, FULL-LENGTH, HUMAN-LIKE GLYCOSYLATED 
ANTIBODIES FOR BIO-DEFENSE 
 
Abstract  
From the point of DNA sequence confirmation until production of meaningful clinical quantities 
of novel therapeutics, current manufacturing systems for many glycosylated proteins, such as 
monoclonal antibodies, require at least several months and often more than a year. 
Consequently, in the event of mass-casualty epidemics from new infectious agents, or 
poisonings from new toxins, current systems will fail to provide sufficient and timely quantities 
of certain emergency medical countermeasures. As the identity of many new biological threats 
are unlikely to be known in advance, pre-emptive manufacturing and stockpiling of 
countermeasures cannot always be performed.  Preparedness for all biological catastrophes 
requires a radical solution to replace the current slow scale-up and manufacture of certain 
lifesaving medical countermeasures. 
 As medical countermeasures, antibodies have the potential advantage of providing 
immediate protection, but the disadvantage of requiring moderate to high dosing levels per 
person.   While subunit vaccines and antibody fragments may be produced in bacteria, yeast, 
plant or insect cells, the majority of full-length antibody manufacturing processes utilize 
mammalian cells.  This is due to their ability to carry out complex assembly and processing, 
including human-like glycosylation, and thus secrete fully active antibodies in the culture fluid, 
often at concentrations of 1 g/L or higher.  Subsequent recovery and purification is readily 
performed using industry standard approaches with high overall yields (70 – 80%).   Current 
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clinical and commercial manufacturing methods use stable cell lines for protein expression, 
wherein the gene coding for the protein of interest is stably integrated into the host cell 
genome.  The generation, identification, banking, testing, and scale-up of suitable stable clones 
generally takes many months. Because this development time is not compatible with 
emergency manufacturing, an alternative method for rapid production of medical counter 
measure antibodies  is needed. One such potential technique is transient gene expression. 
 Transient gene expression is a common approach for production of research-grade 
antibodies.  It is frequently used to generate milligram to gram quantities of material within 
two to three weeks of DNA sequence confirmation. In the past, transient systems have been 
considered for emergency production of large quantities of antibodies, but dismissed due to 
low titers, high cost of DNA, uncertain regulatory environment, and the lack of sufficient, 
available manufacturing capacity. Recent developments, however, have substantially enhanced 
the viability of such an approach. This article will explore these developments and investigate 
the use of transient gene expression for rapid production of antibody-based medical 
countermeasures.   
   
1.1 Recombinant protein production systems needed for catastrophic 
biological events 
 Despite advancements in the use of early detection systems, integrated epidemiologic 
surveillance, vaccination, and use of antimicrobial and antiviral agents, the final line of defense 
against a biological pathogen is the immune system of the exposed individual. Anti-microbial 
and anti-viral therapies may not work on all biological agents, especially resistant strains and 
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toxin-based pathogens. Similarly, vaccination requires a window before protective responses 
are effective, often including multiple injections. Passive administration of 
immunotherapeutics, especially monoclonal antibodies (mAbs), can provide a state of 
immediate immunity that can last for weeks and possibly months.1,2 
 The market demand for bio-defense has been defined, at least in one aspect, by the 
Defense Advanced Research Projects Agency (DARPA) through their Accelerated Manufacture 
of Pharmaceuticals (AMP) program.3 As a starting point, these guidelines represent DARPA’s 
estimate of the production requirements for emergency medical countermeasures sufficient to 
protect US military personnel (~3 million people).  Compared to a civilian population, this 
quantity would translate to 1% of the total US population (~300 million), and would only be 
sufficient for initial clusters of disease outbreak, early responders, and military and police 
forces.  Thus, this 3 million dose estimate defines a low end of the market demand for bio-
defense medical countermeasures, and provides metrics against which one can assess 
alternative capabilities.  
 The AMP program is a three phase system intended to build manufacturing capability 
for both vaccines and antibody recombinant proteins (r-proteins). An interested party could 
apply for Phase 1 funding, which requires production of either 12 Kg of antibody or 1.2 g of 
vaccine within a 90 day period.  If successful, the party could apply for Phase 2 funding wherein 
a 10x expansion of production capabilities would be necessary to generate 120 kg of antibody 
or 12 g of vaccine within a 90 day period. The final phase requires an additional 10x expansion 
of production capability to generate 1200 kg of antibody or 120 g of vaccine within 90 days 
(Table 1.1).  Currently, there are three different partnerships attempting to meet vaccine 
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production targets, all based upon subunit vaccines made through bacterial, fungal and plant 
technologies.4 There has not been, however, any significant progress to date toward hitting the 
much more challenging antibody production targets. 
 
Table 1.1. Milestones for bio-defense 
markets 
Phase  Antibody  Vaccine  
1 12 Kg 1.2 g 
2 120 Kg 12 g 
3 1200 Kg 120 g 
 
 One of the reasons for the lack of success in rapid production of antibodies is an 
absence of private sector bio-manufacturing firms. This is, in part, due to difficult requirements 
in bio-defense markets. The Phase 3 production target of 1,200 Kg of antibody is large 
compared to other biologic products and revenue streams are not predictable. The worldwide 
market for biologics in 2009 was $95 billion with 130 biologic products, which is 11% of the 
total pharmaceutical market and 16% larger compared to the previous year.5 Of these 130 
molecules, 27 biopharmaceutical products had sales in excess of $1 billion of which 17 were 
manufactured by mammalian cell culture.  Nine of these were antibody-based products, 
including full length antibodies, antibody fragments, and Fc-fusion proteins. Of the full-length 
antibodies, only three have production targets larger than those in Phase 3 (Figure 1.1).  
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Figure 1.1. Biologics demand in 2009.  
Estimated demand in 2009 for the top six monoclonal antibody products mammalian cell culture products. Adapted 
from Levine 2010. Requirements were forecasted from previously filed annual reports. 
 
 In order to estimate the possibility of manufacturing 1,200 Kg of antibody material, a 
simplified, estimation model was constructed that evaluates manufacturing processes with a 
range of titers (50- 1500 mg/L) and a range of  bioreactor sizes (500-25,000 L). Antibody 
production output is shown in Figure 1.2.  This estimation model assumes eight dedicated 
production reactors of any given size, production culture durations of 13 days, with a 1-day 
turnaround, resulting in a 2-week cycle time, and 70% downstream yield. This model identified 
a number of configurations that are able to satisfy Phase 1 and Phase 2 goals for antibody 
production. For instance, eight 25,000 L reactors with a final titer of 100 mg/L would be 
sufficient to satisfy Phase 2 targets of 120 kg. Similarly, a process with 1000 mg/L in eight 2,500 
L bioreactors, which may consist of disposable bioreactors, would satisfy Phase 2 production 
targets. Phase 3 targets, however, would require a process with 1000 mg/L and a plant 
configuration of eight 25,000 L bioreactors.  One such plant configuration, Genentech’s 
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Vacaville II plant, is currently sitting idle and could provide sufficient capacity for bio-defense 
production.6  Although not quite as large as the Vacaville II plant, there are additional large-
scale antibody production plants sitting idle elsewhere in the US. 
 
Figure 1.2. Simplified, simulation model to achieve bio-defense production targets within a 12 week period.  
Production model shows the number kg produced within a three month time frame. Production output is displayed 
above each condition. This estimation model assumes eight dedicated production reactors of any given size, 
production culture durations of 13 days, with a 1-day turnaround, resulting in a 2-week cycle time, and 70% 
downstream yield. 
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1.2 Capacity within the biopharmaceutical industry 
 Employment of large scale bioreactors may be able to meet capacity requirements for 
bio-defense. Access to this capacity may occur in a number of fashions. One possibility would 
be through existing installed, stainless-steel bioreactors.  The industry’s proclivity for these 
reactors increased available capacity over the last decade, and based upon current project 
already underway, will lead to further increases in capacity over, at least, the next few years. 
(Figure 1.3).  
 
 
 
Figure 1.3. Biomanufacuting capacity in North America, 2002 projected to 2015. 
Mammalian-based GMP clinical and commercial facilities. Disposable and roller bottles systems were excluded 
from analysis due to the difficulty assessing and forecasting their volume accurately. Adapted from Levine 20105 
and Reynolds 20107.  
 
 Unless a new use is found, such as for medical-counter measure production, large-scale 
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that only 69% of installed mammalian cell bioreactor capacity is currently being used (Figure 
1.4)5. There are two primary reasons for this moderate bioreactor utilization rate.  
 
Figure 1.4. Global capacity utilization for mammalian cell culture. 
Adapted from Levine 20105.  
 
 First, there have been dramatic advances in cell culture productivity. Commercial cell 
culture titers have been doubling similar to Moore’s law, every 3.4 years.8 Commercial cell 
culture processes for clinical production now have titers in the range of 4-10 g/L.9-11  New, 
higher titer processes for established products are regularly approved and implemented for 
commercial production, resulting in reduced manufacturing plant time demands for those 
products.   
 Second, many firms adopt a risk adverse approach to managing capacity, due to both 
the skewed high cost of stocking out compared to the cost of carrying idle capacity, as well as 
the ethical considerations around potentially stocking out of a life-saving drug. Accordingly,  
many firms target the high end of market estimates, while assuming little or no gain in future 
titers,  when they are sizing and designing manufacturing plants.12,13  
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 Due to an abundance of installed stainless steel bioreactors, bio-defense production is 
possible within existing facilities. The 31% of capacity that is currently not being used within the 
industry could satisfy the demands of bio-defense under many scenarios. 
 Another option for bio-defense production is through the use of disposable bioreactors, 
or what is sometimes termed single-use-teachnology (SUT). Because of an escalation of interest 
in SUTs, there have been significant advances in both disopable design and cost.14,15 Compatible 
with nearly all aspects of antibody production, including upstream cultivation as well as 
downstream purification, SUTs are able to provide an end-to-end solution for 
biomanufacturing.16-18  In addition, SUTs are able to be deployed in a variety of manufacturing 
locations, including military Forward Operating Bases (FOBs), which may include sterile 
warehouses, supply depots, or mobile manufacturing facilities. Such installations may result in 
on-site, on-demand manufacturing capacbilities. With a plethora of possibile capacity 
configurations, selection of a feasible cell culture process is essential.  Selection of such a 
process includes determining an optimal host and expression system, which will be discussed 
below. 
 
1.3 Antibodies require complex assembly 
 All human antibodies, or Immuno-Gamma globulins (IgG), contain a glycosylation site at 
an asparagine residue (N297) in the Fc domain (Figure 1.5).19  Other antibody isotypes often 
contain additional N-linked and O-linked glycans in the Fc domain and hinge region. In addition, 
30% of human IgG antibodies contain N-linked glycosylation sites within the Fab domains, 
primarily attached within the variable regions (VH and/or VL).20,21 
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A 
 
B 
 
 
Figure 1.5. Antibody molecule with glycosylation profile. 
A) Structure of the IgG molecule including variable (V) and constant (C) regions as well as heavy (H) and light (L) 
chain components. Figure adopted from Peterson et al. 200645.  B Glysocylation patterns between expression 
systems, adapted from Jena 201246. 
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 There are a number of ways these glycosylation moieties modulate both In vivo potency 
and In vitro stability of an antibody. The glycan at N297 in the Fc domain can affect protein 
resistance to proteolysis and the propensity to aggregate In vitro.22,23  Early studies with human 
mouse chimeric IgG1 indicated that altered glycosylation can increase sensitivity to enzymatic 
digestion.24 Moreover, certain glycan patterns confer greater protection to proteolysis than 
others.25,26 Similar to enzymatic digestion, the thermal stability of full-length antibodies 
decreases when glycosylation is removed.27  
 Glycosylation is also important for therapeutic efficacy. Upon antigen binding, 
antibodies form an immune complex which mediates the recruitment of complement proteins 
and triggers immune response signaling through Fc receptors (FcγRs).28 Antibodies destroy 
pathogenic cells through antibody-dependent cellular cytotoxicity (ADCC) and antibody 
dependent cell-mediated phagocytosis (ADCP). These mechanisms rely on the interaction 
between glycosylation of the antibody and the FcγRs.29-34 Often, proper glycosylation is critical 
for therapeutic outcome. 
 Glycan heterogeneity in therapeutic antibodies is affected by many factors, including 
expression system host (i.e. mammalian, plant, yeast, and transgenic animals), the particular 
cell line (e.g., CHO vs. NSO), culture milieu, and downstream processing.35 To date, all FDA-
approved therapeutic antibodies have been produced in either CHO cells or in mouse myeloma 
cells (NS0 or SP2/0).36 Mammalian cell expression systems, especially CHO, have been preferred 
as their protein glycosylation machinery largely resembles those found in humans37,38 and they 
can be cultured to high densities in chemically-defined medium.  Along these lines, certain 
mammalian expression systems such as CHO are preferred as others  may induce undesired 
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immunogenicity in humans, or reduce therapeutic efficacy. For example, Cetuximab™ produced 
in the murine myeloma cell line SP2/0 is a chimeric mouse–human IgG1 monoclonal antibody 
that binds the epidermal growth factor receptor (EGFR). 22% of patients treated with 
Cetuximab™ had severe hypersensitivity reactions, characterized by human anti-mouse 
antibodies (HAMA), that were specific for the mouse produced glycan.39 
 While mammalian systems are the preferred expression system for glycosylated 
antibodies, CHO cells are preferred over other mammalian expression systems. There has been 
significant progress in rapid manufacturing using Human Embryonic Kidney (HEK) cell lines 
because of a natural episomal system that maintains plasmids more effectively than other cell 
lines.40,41 HEK, however, have been found to produce altered glyscoylation, while CHO have 
been shown to reproducibly produce human like glycosylation.42-44 Therefore, the use of CHO 
cells as the expression system is preferred for the production of full-length, human like 
glycosylated antibodies for bio-defense.  
 
1.4 Anti-infective antibody success 
 Passive antibody preparations have been generated against a number of biological 
pathogens. These include many of the Class A, B, and C agents, such as RSV, Vaccinia, Hepatits B 
and C, Dengue, HIV, Ebloa, Nipah, Incluenza, Bacillus anthracis and its toxin, Yersinia pestis, 
Clostridium botulinum neurotoxin, and many others.47,48  Success of many of these molecules 
result from three inter-related characteristics. First, the antibody targets biologically relevant 
epitopes on the pathogen or toxin of interest with high affinity. Second, the antibody has a long 
serum half-life. Last, the antibody leads to effective pathogen clearance.49,50  Antibody-
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mediated clearance of the antigen is typically associated with accumulation of the antibody-
antigen complexes in the liver and/or spleen.51 Neutralization of bacterial toxins has been 
shown to be dependent on maintaining antibody interaction with FcγRs through proper 
glycosylation.52 In fact, one study demonstrated that an antibody preparation imparted 
significant protection against the botuliunum neurotoxin only when a full-length, human-
glycosylated antibody was present.  The authors hypothesized that the full- length antibody 
provided a clearance mechanism where toxin was removed from the system.53 
 
1.5 Rapid expression utilizing CHO 
 Commercial cell culture expression systems utilize stable gene expression (SGE) 
platforms to produce r-protein. SGE processes include identification of the antibody DNA 
sequence, which is then cloned into a plasmid expression vector and transfected into CHO cells 
where the plasmid is stably integrated in the host genome. Cells are subjected to multiple 
rounds of amplification wherein the gene of interest is amplified and specific productivities are 
increased up to 25-50 pg/cell-day or higher. Amplified cells are tested for stability and 
characterized through a battery of tests. Ultimately this strain selection process generates a 
clonal Master Cell Bank (MCB), which contains cells that will be used exclusively throughout 
commercial manufacture. Cells within the MCB typically have high rates of protein production, 
fast doubling times, and reproducible operating characteristics.54-56 MCB generation is, 
however, a costly and lengthy process (from 4-12 months; Figure 1.6A). Once the MCB is 
generated, inoculum is created by expanding cell mass through a series of cultures. Expanded 
inoculum is cultivated in a production bioreactor, where media formulation and culture 
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conditions are optimized for r-protein production. R-proteins are subsequently purified through 
centrifugation, filtration and column chromatography. These purification operations remove 
host cell proteins, host cell DNA, endogenous retrovirus, and other impurities, creating the drug 
substance. The process culminates in a final vialing step, often called fill/finish to generate the 
final product.57,58 
 
A 
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B 
 
Figure 1.6. Process flow diagram of CHO cell culture manufacturing operations. 
A) Stable gene expression and B) Transient gene expression. Shared operations are shown in orange while unique 
operations are shaded in either red or green 
 
 
 Transient gene expression (TGE) utilizes the same downstream platform as SGE, but 
does not require the timely development of a master cell bank (Figure 1.6B). Instead of an 
MCB, TGE relies on cultivation of an aggregate pool of transfected CHO cells, in which the gene 
of interest is maintained extra-chromosomally. As plasmid DNA is not maintained throughout 
subsequent generations, new pools of transfectants must be created for each batch of 
production. TGE is, therefore much more rapid than SGE, but suffers from low specific 
productivities, and thus, overall titer. In addition, the high cost of DNA increases the cost of 
goods manufactured (COGM) of drug substance. A comparison of the two different systems 
(Table 1.2) demonstrates the advantages and disadvantages of each system. 
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Table 1.2. Transient versus stable gene expression in mammalian cells 
 
Transient expression Stable expression 
Expression of transfected genes are usually 
within 16-96 h, but expression is not 
propagated through subsequent generations 
 
Transfection requires a large amount of plasmid 
DNA  
 
Expression level usually is relatively low 
(5-100 mg/L) 
 
Expression product is good for pre-clinical 
assessment, but no clear guidelines for clinical 
production 
 
It takes only a short period to expression of a 
product for “Proof of Principal” demonstration 
Heterologous DNA is integrated into the host 
genome and is stable throughout many 
generations 
 
Cell line development and testing requires an 
extensive period (4-12 months) 
 
After amplification and high producer selection, 
expression level is relatively high (1,000-10,000 
mg/L) 
 
Stable cells lines can be used for large scale 
manufacturing leading to clinical trials and 
commercialization 
 
 
 
1.6 Current state of transient gene expression 
 While transfection protocols have yet to be standardized, many components in the r-
protein production process through TGE is similar to those found in SGE; including seed train 
expansion, harvest, purification, fill and finish.54 Transient systems provide the same high 
quality protein, just much more quickly.40 Several methods for gene transfer have been 
optimized for chemically defined transfection of animal cells, including both viral and non-viral 
methods.  
 Viral transient transfection includes the use of adeno-, alpha-, baculo-, lenti-, retro- and 
vaccina virus particles. Although these vehicles are very effective at delivering intact plasmid 
DNA into the nucleus, their use is limited due to limited DNA carrying capacity, lengthy 
processes for recombinant virus isolation, viral stock amplification and titration, bio-safety 
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issues, and high cost of production.59 Furthermore, viral-based processes are not allowed in any 
of the current large scale cell cultures plants, such as those built and operated by 
biopharmaceutical manufacturing firms. This is because it is difficult to validate cleaning, 
generating significant turnaround time and increases contamination risk for subsequent non-
viral based production. 
 Non-viral methods for transient gene expression can be separated into mechanical and 
non-mechanical. Mechanical methods include microinjection, electroporation and others. 
These methods have been shown to have extremely favorable transfection efficiency, which is 
defined as the percentage of intact plasmid DNA actively transcribed in the nucleus. However, 
these methods are currently not viable for large-scale cell culture because of both technical and 
economic reasons in their inability to scale above bench size. 
 Non-mechanical methods utilize calcium phosphate, cationic lipids, cationic polymers, 
and other nanoparticles, such as chitosan derivatives, to tightly condense DNA and form 
positively-charged complexes. Through electrostatic interaction with the negatively-charged 
cell membrane, DNA-complexes endocytose into the cytoplasm via endocytosis and eventually 
escape the endosomal vessicle. The DNA-complex can traffic through the cell’s cytoplasm into 
the nucleus, or transnucleate, through various pores on the nuclear envelope or, more 
commonly, through the breakdown of the nuclear membrane during mitosis. During this 
process the DNA-complex dissociates to allow for transgene expression. Transfection efficiency 
is low for non-mechanical methods due to the many physico-chemical barriers the cell has 
developed over thousands of years of evolution to prevent foreign DNA uptake.60 However, 
transfection agents are believed to increase efficiency by facilitating the internalization into the 
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cell and escape from endosomal/ lysosomal vesicles, as well as protecting DNA from 
cytoplasmic nucleic acid degredation. Each of the various transfection agents has distinct 
advantages and limitations, discussed below.  
 Developed in the late 70’s, calcium phosphate was the first transfection agent used in 
mammalian cells and has been subsequently optimized up to the 100-L scale. Calcium 
phosphate’s dependence on serum for transfection, as well as buffer exchange steps post-
transfection, limit its use in large scale cell culture.61 Cationic lipid-based transfection 
(lipofection) has shown promise with high transfection efficiency; however, the cost of these 
compounds may exclude their use at large scale. Transfection methods employing cationic 
polymers seem to be the most actively used in the literature. Polyethelenimine (PEI) is currently 
the most widely used transfection agent because it is cost efficient, easy to handle and provides 
relatively high transfection efficiency as compared to alternative reagents.62 
 PEI is available in various configurations with average molecular weight ranging from 2 – 
750 kDa in either branched or linear forms. The 25 kDa linear PEI has been shown to be the 
optimal PEI for transfecting cells; its protocol and mechanism of delivery has been well 
studied.63,64  Briefly, PEI, with a high cationic charge density, condenses DNA to form a compact 
positively-charged particle. This particle is endocytosed, and escapes endosomal vesicles 
through the proton-sponge effect, in which basic nitrogen atoms become protinated and cause 
an influx of chloride ions which rupture the vesicle through osmotic swelling.65,66 Released 
plasmid DNA may transnucleate through complex methods mentioned above. Various cell types 
have been transfected using PEI at scales ranging from 1 ml to 1000-L. Over the years PEI has 
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proven itself to be one of the most cost effective and efficient means of DNA delivery into 
mammalian cells. 
1.7 Recent advances in TGE protocols 
 The considerable and ever-increasing number of publications on transient transfection 
technologies employed for r-protein production reflects the success of this approach over the 
past decade. Mirroring the advances in commercial cell culture, significant process 
development has improved TGE titers (Table 1.3). Media development, strain modification and 
optimization of transfection protocols have produced process that generate up to 1 g/L 
antibody quantities within two weeks.67 Many of these approaches maintain cell viability while 
decreasing growth rates.68 Both hypothermia and media supplements to induce gene 
expression are methods that decrease growth rates, extend viability and increase titer.41 In 
addition, increased cell density during transfection results in both a greater utilization of DNA 
and produces cells with higher specific productivities.69  
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Table 1.3. Antibody products produced with PEI-mediated TGE processes in mammalian cells 
Expression 
(mg/L) 
Cell Process Reference 
1000 HEK 293* Fed-batch, high density transfection with  
plasmid cocktail, hypothermia and gene 
expression additives  
67 
300 
 
CHO-S Batch transfection at moderate densities, 
optimized PEI/DNA/cell ratios, 
hypothermia 
 
70 
90 CHO DG44 Use of valproic acid, hypothermia, 
moderate transfection densities  
71 
80 CHO K1SV Fed-batch with DMSO and LiAC* 42 
80 CHO-T Episomal replication system, batch 
transfection at low density 
72 
25 DG44 Low density transfection 73 
22 DG44 Disposable orbital bioreactors 74 
* HEK-293 cells are high producers, yet glycosylate unfavorably; DMSO (dimethyl sulfoxide); LiAC 
(Lithium Acetate) 
 
 
1.8 Conclusions 
Rapid manufacture of full-length, human-like glycosylated antibody based medical 
countermeasures is an unmet medical need. Because of improvements in titer, availability of 
installed stainless steel and SUT capacity, and improved process performance, TGE is a viable 
method to meet this need. Further investigation into large scale TGE production capabilities is 
necessary for an optimal bio-defense strategy.  
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CHAPTER 2. ENGINEERING CONSIDERATIONS FOR LARGE 
SCALE TRANSIENT GENE EXPRESSION OF MONOCLONAL 
ANTIBODIES IN CHO CELL CULTURE 
 
Abstract 
Transient gene expression could potentially provide sufficient quantities of full-length, human-
like monoclonal antibodies as medical countermeasures in the event of mass casualty biological 
catastrophe. This rapid method of protein production has been scaled to hundreds of liters to 
provide gram scale quantities of research-grade protein, yet further increases in scale are 
needed to fulfill rapid response needs. Many transient operations parallel those found in stable 
gene expression, which have been successfully scaled up to 25,000 L. This work aims to 
characterize aspects of transient gene expression that are distinct from those found in stable 
expression and key to the scale-up of TGE production. A concentration dependent transport 
model was constructed to evaluate potential mass transfer limitations which may be 
encountered upon scale-up. As a critical component of this model, PEI/DNA particles were 
characterized through dynamic light scattering and were found to be larger and more complex 
than previously reported. The mass transport model helped explain certain complex trends that 
involve trade-offs between the cytotoxicity of PEI/DNA polyplexes and the specific productivity 
of transfected cells. The model also predicted the impact of mixing and diffusion limited 
polyplex transport upon scale up to industrial sized bioreactors.  
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2.1 Introduction 
 Transient gene expression (TGE) has become a standard method for rapid production of 
milligram to gram quantities of recombinant protein (r-protein). The need for r-proteins with 
post-translational modifications, including monoclonal antibodies, has fostered the 
development of mammalian-cell based transient expression systems (Durocher and Butler 
2009).1 While transfection protocols have yet to be standardized, suspension-adapted 
mammalian cells, especially Chinese hamster ovary (CHO) and Human Embryonic Kidney- 293 
(HEK-293) cells, have dominated the literature. For HEK-293 cells, titers up to 1 g/L monoclonal 
antibody have been reported (Backliwal et al. 2008),2 while CHO processes report 20-300 mg/L 
in batch cultures (Rajendra et al. 2011; Pham et al. 2006; Baldi et al. 2007; Galbraith et al. 
2006).3-6 Many of these processes employ high density cultures (20*106 cells/ml), direct 
addition of  plasmid DNA and linear 25 kDa polyethylenimine (PEI), followed by a feed of both 
production media and additives to increase gene expression. These high-density methods, 
however, have not been scale-up to bioreactors larger than a few liters. Current TGE protocols 
do not meet rapid response needs of bio-defense, and an unmet medical need still exists. 
 Stable gene expression (SGE) in CHO cells, on the other hand, has been employed for 
dozens of FDA-approved therapeutic molecules including monoclonal antibodies at large scales 
(Geisse 2009).7 Production processes have been rigorously characterized and optimized up to 
the 25,000 L scale.  Critical operations in SGE r-protein production include; expansion of 
inoculum from frozen cell vials, media exchange of spent media prior to production phase (for 
some processes), cell cultivation in production bioreactors, which includes: pH control with 
base addition, DO control with sparged gas, removal of CO2 with sparged gas, nutrient addition 
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(fed-batch), and backpressure control (Table 2.1). For many cell cultures operations, TGE 
employs the same techniques as SGE, and is therefore likely to be successfully scaled without 
difficulty. There are, however, differences encountered between the two expression methods, 
Table 2.1 identifies these similarities and differences. One goal of this study was to investigate 
how the operations unique to TGE may be affected by scale and predict the success of large-
scale TGE production. 
Table 2.1. Large-scale CHO cell culture in stirred tanks  
Unit Operation SGE TGE 
Expansion of inoculum 
from frozen cell vials up to 
5000-L 
Well established Likely same as SGE 
Media exchange of spent 
media prior to production 
phase 
Successfully employed at 
2400-L N-1 scale for 
certain processes 
Possible scale-up to larger 
systems 
Cell cultivation in 
production bioreactor up 
to 25,000-L Scale 
Well established Likely same as SGE 
pH control with bulk 
mixing of added base 
Well established Likely same as SGE 
DO control with sparged 
gases (air and oxygen) 
Well established Likely same as SGE 
Removal of CO2 with 
sparged gasses 
Well established Likely same as SGE 
Nutrient additions 
through fed-batch 
Well established Likely same as SGE 
Backpressure control Well established Likely same as SGE 
Transfection of cells with 
pDNA and PEI at 2500-
5000-L Scale 
N/A 
Explored in this article 
using engineering analysis 
and experimentally using 
scale down models 
Cultivation of recently 
transfected cells at scales 
up to 25,000-L 
N/A 
Recently transfected cells 
may be more shear-
sensitive than standard 
SGE CHO 
 
 TGE unit operations that differ from standard SGE include media exchange of spent 
media prior to production, transfection of cells with plasmid DNA and PEI, and maintenance of 
transfected cells. Media exchange has been employed at the 2,400 L scale for commercial 
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production of certain r-proteins and is not likely to differ for transient systems. Similarly, 
cultivation of transfected cells is most likely not significantly different from high density SGE 
cultivation beyond a possible increase in shear sensitivity. Transfection of cells is the primary 
step that may be affected by scale. Transfection at larger scales may be influenced by a number 
of factors including DNA/PEI nanoparticle formation, (polyplex formation), bulk mixing, polyplex 
transport to the surface of the cell, and hydrodynamic forces acting on the cells during 
transfection.  
 Many of these interrelated phenomena are impacted by aeration and agitation and  are 
critical factors for animal cell cultivation. Scale-up tradeoffs between various agitation and 
aeration regimes have been rigorously studied for stable cell culture (Dusting et al. 2006; 
Garcia-Ochoa and Gomez 2009; Zhang et al. 2010).8-10 Increases in scale typically result in both 
an increase in heterogeneity of shear forces, fluid velocities, circulation times in stagnant zones, 
and mixing times, as well as a decrease in the smallest Kolmogorov eddy length (Lara et al. 
2006; Xing et al. 2009; Tissot et al. 2010).11-13  
 PEI-mediated TGE is composed of a number of steps, illustrated in Figure 2.1. The steps 
are a combination of both chemo-physical phenomena that can be modeled using 
concentration dependent mass transfer equations, and biological processes that are related to 
cell physiology and health. Scale-up of mixing and agitation equipment for large-scale 
transfections could impact process performance at the cellular level in a number of ways. These 
factors could influence transfection by altering: (1) the complex formation rates; (2) mass  
transfer of polyplexes from the culture medium to the cell surface; (3) internalization rates of 
polyplexes; (4) the hydrodynamic stresses on the cell;  or  (5&6) the physiological health of cells 
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in less defined ways. Many of these effects occur simultaneously, resulting in tradeoffs and 
intermediate optima.   
 
Figure 2.1. Overview of the transfection process. 
 (1) DNA condensation through electrostatic interactions with transfection agent. (2) This interaction will eventually 
form a stable polyplex. (3) Polyplexes transport to the surface of the cell and are internalized through various non-
specific endocytosis mechanisms. (4) Complexes eventually escape endocytotic vesicles through the proton sponge 
effect. (5) DNA is liberated from the complex. (6) Intact DNA is transported to the nucleus through complex, and 
unclear mechanisms. Once plasmid DNA enters the nucleus it is transcribed and translated for protein production.  
 
   
2.1.1 Optimal DNA per cell 
 One important aspect of transfection is the amount of DNA entering each cell. Too 
much DNA entry and cytotoxic effects are observed. (Fischer et al. 1999; Godbey et al. 2001; 
Godbey and Mikos, 2001; Godbey et al. 2001; Putnam and Langer, 1999; Rajendra et al. 2011; 
Biollin et al. 2011).4,38-43 This cytotoxicity is caused either by foreign gene responses, cellular 
membrane disruption, endosomal swelling and rupture, or autophagy (Fischer et al. 1999; 
Beyerke et al. 2010; Gao et al. 2011).38, 44, 45 While too much DNA entry to the cell is cytotoxic 
and suboptimal, too little DNA entering the cell is also suboptimal. Too little DNA entering the 
1 
2 
3 
4 
5 6 
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cell does not provide a cell with sufficient capability to produce protein in high levels (high 
specific productivity, Qp). Therefore, there is an optimal range of the amount of DNA entering 
each cell, shown in Figure 2.2.  
 
Figure 2.2. Dose-dependent cytotoxicity and specific productivity of PEI mediated TGE. 
The blue line represent the results from transfections. Each section on the graph represent a scenario characterized 
by either I. Too little DNA/cell and transfected cells lack sufficient productivity; II. an optimal transfection 
paradigm; III. Too much DNA/cell and transfected cells die.  
 
2.1.2 Transport 
 The amount of DNA entering the cell is a function of the hydrodynamic environment 
that surrounds the cell. DNA found in the bulk culture fluid is internalized by a cell only when in 
proximity to the surface of the cell. DNA particles are transported to the surface of a cell in a 
concentration dependent manor by a combination of diffusive and convective forces. One goal 
of this study was to construct a mass transport model and investigate the scalability of TGE. 
DNA/Cell 
Titer 
 
I. 
Low Qp 
II. 
Optimal 
III. 
High Cytotoxicity 
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While a number of phenomenological observations have been made governing the kinetics and 
mechanics of PEI mediated gene transfer, a phenomenological model including hydrodynamic 
effects on mass transfer has not been proposed.  Viral mediated gene transfer, on the other 
hand, has been studied for over 50 years and several complex-attachment based mass transfer 
models have been proposed (Tang and Szoka 1997; Orgis et al. 1998; Goula et al. 1998; Godbey 
et al. 1999. Bertschinger et al. 2008; Hufnagel et al. 2009; Han et al. 2009; Palumbo et al. 
2012).14-21 Transport of viral particles from the bulk culture fluid to the cell is a relatively slow 
process compared to the transport of proteins or nutrients, due to larger particle sizes and 
lower diffusivity coefficients.  It is now generally accepted that virus-cell contact can be 
represented by a simple diffusion controlled process through an exponential decay function 
with various corrective factors (Chillakuru et al. 1991; Mittereder et al. 1996; Nyberg-Hoffman 
et al. 1997; Chuck et al. 1996; Gilbert et al. 2007; Tayi et al. 2010).22-27  This work similarly 
employed an expediential decay function based off of the size of polyplex in a turbulent cell 
culture vessel to explain results from transfection experiments in shaker flasks and predict the 
scalability of transfection. 
 
2.1.2.1 Model construction  
 Concentration dependent mass transfer analysis was conducted for a model system 
composed of a homogeneous suspension of CHO cells in chemically defined media in a stirred 
tank bioreactor agitated by an impeller (e.g., Rushton or pitched-blade), which rotates at a set 
stirrer speed. Most studies involving macroscopic diffusion of spherical, membrane-adsorbing 
particles assume diffusion occurs in a semi-infinite stagnant film around each cell and that 
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adsorption on the cell surface is both instantaneous and irreversible. Therefore the diffusivity 
coefficient (DF) can be calculated through the Stokes-Einstein equation (Doran 1995)
30 
  	
           (1) 
Where kB is the Boltzmann’s constant (1.38*10
-23 JK-1), T is the absolute temperature (310°K), η 
is the fluid viscosity for protein-free medium (7.1 *10-3 g/cm-sec; Anunins and Henzler 1988)31 
and r is the particle radius. For a PEI/DNA complex suspended in a turbulent vessel, mass 
transport of the complex from the bulk medium to the cells can be described by a 
dimensionless Sherwood number (Doran, 1995).30 For transport to spheres such as cells in 
turbulent vessels, one can use the following equation put forth by (Sano et al. 1974; Chaudhari 
and Ramachandran 1980).31,32 
ℎ = 2 + 0.4 



/
         (2) 
Where Sh is the Sherwood number,  is the average power dissipation per unit mass ( assumed 
to be 100 cm2/sec3), Dc is the diameter of a CHO cell (assumed to be 15 μm) and ν is the 
kinematic viscosity (7.03 *10-3 cm2/sec). For liquid phase transport, the Sherwood number can 
be written as the ratio of overall to diffusive mass-transfer rates through the boundary layer to 
a spherical cell, or    
ℎ =  !            (3)  
Where kL is the liquid phase mass transfer coefficient. Near the cell-liquid interface, the fluid 
velocity is reduced and a boundary layer develops. If the particle is immediately internalized by 
the cell (Ci = 0), the concentration difference between the bulk liquid and the phase interface 
drives mass transfer of the particle from the liquid to the cell within time Δt, described by 
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"# = "#,%&'((*+)          (4) 
Where C0 is the concentration of the particle in the bulk liquid and Ci is the particle 
concentration at the cell surface, a is the liquid-solid interfacial area per unit volume described 
by - = 	4/012, where X is the cell density in the fluid (20*106 cell/ml).  Therefore the rate of 
change of the complex concentration in a turbulent, vessel between two time points (t1 and t2, 
where t2>t1) can be mathematically represented by 
"# = "#,%&
345
5
67(8&89)
        (5) 
For simplification, the half-life of polyplexes in the bulk media can be estimated as  
 : = ;<1=>?@
5 6ABC
7
          (6) 
These equations were simulated using Microsoft Excel 2010 using best parameter estimates 
from experimental observations. After constructing the model, mass transport of polyplexes 
was calculated while varying certain parameters, such as polyplex size, cell density, and 
agitation in order to investigate their effect on transfection.  
 
2.1.2.2 Calculate polyplex size effect on mass transport  
 The size of the polyplex would alter its diffusivity coefficient. Using Equation 1, a range 
of polyplex diffusivity coefficients were calculated. Polyplex diameters of 60-2000 nm were 
modeled, whose DF ranged from 5.33*10
-9 to 1.60*10-10 cm2/sec. This range of DF was used to 
calculate mass transfer rates based off of a Sherwood analysis with Equation 6. The Sherwood 
number was 2.4 with an assumed power input of 100 cm2 s-1.  A substantial increase in half-life, 
or Kd, was observed with increasing polyplex size (Figure 2.3). This Kd represents the time scale 
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when half of the plasmids arrive at the cell surface and was calculated to be between 30 
seconds and 5 minutes with larger polyplexes arriving at a slower rate than smaller polyplexes.  
 
Figure 2.3. Calculated tansport of polyplexes versus size. 
Calculated effect of polyplex size of mass transfer rates using assumptions listed in model construction section. 
 
2.1.2.3 Calculate cell density effect on mass transport  
 Many groups have investigated the ratio of Cell/DNA/PEI and found conflicting optimal 
ranges (Codamo et al. 2010, Backliwal et al. 2008, Rajendra et al. 2011).3,4,37 In order to 
understand cell concentration’s effect on transfection, mass transport of polyplexes to the cell 
surface was modeled by varying cell density from 1 to 30 million cells per ml (Figure 2.4). While 
holding DNA:PEI constant and varying cell concentration, polyplex per cell changes or X in 
Equation 6. Low density cultures have large time scales (Kd) for polyplex transport, 
approximately 1 hour, whereas high density cultures have much shorter time scales, under two 
minutes. There was a steep decline in Kd as the cell density increased between 1 and 10 million 
cells per ml. Increases beyond 10 million cells per ml, displayed a marginal decreases in Kd. 
These observations indicate that a polyplex diffusion limitation may exist during transfections. 
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An observation that highest titer transfection processes employ high density transfections 
further confirms the mass transport model. (Backliwal et al. 2008).4  
 
Figure 2.4. Calculated cell density effect on transfection. 
Mass transport of polyplexes were modeled using a range of cell densities (X) using equation 6.  
 
2.1.2.4 Calculate agitation effect on mass transport  
 Increase in agitation would affect polyplex formation rates as well as increase the 
convective force driving mass transport. Increase in agitation would increase power dissipation 
per unit mass (), thus influence the Sherwood number Equation 3.  has not been rigorously 
calculated for 125 ml shaker flasks, but approximate values have been predicted between 5 and 
35 W m-3 (Barrett et al.  2010). In a 30 ml culture, the associated ε values range from 1500 and 
10500 cm2 s-3. A wide range of values for ε were modeled and the half-life of complexes in the 
bulk media was predicted using Equation 6 (Figure 2.5). There was an exponential relationship 
between agitation and time scale of complex arrival at the cell surface. Increases in agitation 
enhance mass transport during transfection. 
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Figure 2.5. Calculated effect of agitation on polyplex mass transfer. 
A 30 ml shaker flask with a range of power dissipation rates was used to model the mass transfer rate of a 600 nm 
polyplex. 
 
2.1.2.5 Bulk mixing and scale-up considerations 
 Bulk mixing is important to ensure a macroscopic-level homogenous concentration of 
nutrients, cells, gases and polyplexes through the bioreactor. In shaker flasks, time scales for 
mixing are very short (<0.1 min). Larger bioreactors (1-100 m3), however, have much larger 
mixing times, on the order of 0.5-2 minutes (Doran 1995).30 Bulk mixing is most likely not a 
limitation of polyplex transport in shaker flasks, but may affect mass transport in larger 
bioreactors. A comparison of mixing times at various scales is illustrated in Table 2.2. Using 
equation 6 with a range of sizes for polyplexes, we calculated the ratio of times scales, which 
indicate time scales of bulk mixing in industrial bioreactors is larger than the time scale of 
diffusion for the smallest size polyplexes, and is equivalent to that for medium sized polyplexes. 
Therefore, bulk mixing time is a parameter that must be considered for large scale bioreactors. 
Nevertheless, the time scales for the biological processes related to transfection, such as 
polyplex uptake, intracellular polyplex trafficking, transnucleation and transcription are much 
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greater than 30 minutes, and much longer than the times scales for bulk mixing or diffusion of 
the polyplex from the medium to the cell. Therefore, the slower mixing upon scale-up of 
agitation and aeration for larger scale bioreactors most likely would not negatively affect the 
transfection process. 
 
Table 2.2. Time scales for various transfection operations 
Process Condition Time 
Bulk mixing of transfection 
reagents 
Shakers <0.1 min 
Lab-scale Bioreactors <0.5 min 
Industrial Bioreactors (1-25 m3) 0.5-2.0 min 
Diffusion of polyplex from 
media to cell, immediate 
absorption (with Ci = 0) 
polyplex size= 1200 nm <3 min 
polyplex size= 600 nm <1.5 min 
polyplex size= 70 nm <0.5 min 
Biological processes related to 
transfection (uptake, 
intracellular trafficking, etc…) 
 
>30 min 
 
  
2.2 Materials and methods 
2.2.1 Plasmid constructs 
The 8118 base pair plasmid used in this study was p6G4V11N35E.choSD.10 (ATCC -HB-11722), 
which encodes for a humanized IgG antibody. Plasmids were purchased from a commercial 
vendor (Nature Technology Corporation, Lincoln NA).  
2.2.2 Cell culture 
Experiments were conducted with Freestyle CHO-S cells (Life Technologies, San Diego, CA), a 
CHO line derived from CHO-K1 that is pre-adapted to chemically defined, suspension culture 
(Deaven & Petersen 1973; D'Anna 1996; D'Anna et al. 1997).28-30  Cells were cultured in either 
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chemically defined ProCHO5 media (Lonza, Basel, Switzerland) supplemented with 4.1 mM L-
glutamine, HT supplement (Life Technologies) or OptiCHO media (Life Technologies) 
supplemented with 8mM L-glutamine. Cells were passaged every 3-4 days at densities ranging 
from 0.3*106 cells/ml to 5.0 *106 cells/ml (more dense passaging was used for inoculum 
expansion). Cells were cultivated in 125 ml shaker flasks (Corning) operated at 30 mls of culture 
volume, placed in a large, humidified incubator (Thermofisher) at 37°C, 8% CO2. The shaker 
cultures were agitated on a rotary shaker (New Brunswick) at 130 rpm. 
2.2.3 Shaker flask transfections  
Cells were transfected in 125 ml shaker flasks using a modified XLG protocol (Backliwal et al. 
2008). Expanded inoculum was centrifuged prior to transfection and, if not otherwise specified 
resuspended at a cell density of 20*106 cells/ml in ProCHO5 media. DNA was added to a final 
concentration of 50 µg/ml directly to the cells. This was immediately followed by addition of 
the appropriate amount of a 1 mg/ml solution of 25-kDa polyethyleneimine (PEI; Polysciences) 
to a final concentration of 100 µg/ml. 3 hours after transfection, cells were diluted with fresh 
media supplemented with 3.8 mM valproic acid to final cell density of 4*106 cells/ml. Cultures 
were performed in triplicate and maintained with agitation at 31°C for up to 10 days. 
2.2.4 Cell, protein and metabolite analysis 
Viable cell density (VCD), viability, and cell size were determined using a Beckman Coulter Vi-
Cell Viability Analyzer (Beckman Coulter). Supernatant samples were centrifuged, and then 
stored at −80°C for further analysis. Integrated viable cell density, determined from the sum of 
interval contributions, where each contribution was calculated using:  
		DEFGDEF91 ∗ (I2 − I1)          (1) 
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Where VCDtx is the viable cell density at time x in million cells per ml, and t is the time in hours.  
The antibody (IgG) concentration in the culture medium was determined by sandwich ELISA as 
previously described (Meissner et al., 2001; Pick et al. 2002).28,29 In short, goat anti-human Fc 
(Sigma, St. Louis, MN) was used for coating the ELISA - plates, and the synthesized IgG protein 
was detected with horse radish peroxidase (HRP)-conjugated goat anti-human IgG-Fc (Sigma). 
OPD (Sigma) was used as a substrate for the HRP. Absorption was measured at 450 nm using a 
microplate reader (SPECTRAmax340; BioRad, Herceles, CA). Specific productivity (Qp) was 
calculated as titer/IVCD. 
2.2.5 Polyplex sizing  
Polyplex size was determined by dynamic light scattering (DLS). Complexes were formed in a 50 
ml falcon tube (BD biosciences, San Jose, CA, USA) with 25 µg DNA and 50 µg PEI in a volume of 
500 ml of either water, or ProCHO5 media. Samples were subjected to agitation on an orbital 
rotating platform for five minutes before aliquoting into a cuvette and measuring size with a 
Malvern Nanosizer (Brookhaven, Holtsville, NY, USA). Laser wavelength was 514.5 nm and 
carried out at a fixed angle of 90°. Measurement times were automatically calculated by the 
nanosizer. The approximate molecular weight (MW) of DNA mass was calculated using an 
online nucleic acid algorithm for double stranded DNA from (Life Technologies). 
 
2.3 Results and discussion 
2.3.1 Particle size of DNA/PEI complexes in room temperature agitated media 
 In order to characterize DNA/PEI transfection particles in cell culture, polyplex size in 
ProCHO5 culture medium was examined as a function of agitation in spin tubes. Polyplexes 
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were formed by agitating a DNA/PEI/media solution for 5 minutes at either 100 or 200 rpm in 
conical falcon tubes at room temperature before measuring with DLS. Neither media with just 
PEI nor media with just DNA provided measureable particles. Therefore, any observed particles 
in DNA/PEI/media were the result of DNA/PEI complexes. As a control, polyplexes were tested 
in water and were 60±7 nm (Figure 2.6A). This result is in good agreement with the 57±14 nm 
size particles determined by other light scattering measurements (Blessing et al. 2001)33 and 
70±10 nm size particles determined by two photon fluorescence correlation spectroscopy 
(Clamme et al. 2003).34 A much more dynamic range of complex size was observed in cell 
culture media however. Polyplex particle size changed in time with a general trend of 
decreasing diameters. Moderately-agitated transfection complexes (100 rpm, Figure 2.6B) 
ranged from 1000-500 nm in diameter, whereas, highly-agitated complexes (200 rpm, Figure 
2.6C) had a wider size range of 1300-200 nm. The time scale of the decreasing polyplex size can 
be characterized by the time the polyplex shrank to 50% from their original size. This was 
roughly 10 minutes for the highly-agitated complexes, and over 30 minutes for the moderately-
agitated complexes. The variability of polyplex diameter was low throughout the time course, 
as the R2 to a 3rd degree polynomial best fit line was >90%, indicating that polyplexes were 
monodisperse. 
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C 
 
Figure 2.6. Particle size versus time. 
Each dot in A-C represents one DLS measurement of 25 µg of DNA and 50 µg of PEI incubated in 500 ml of 
solution. Polyplexes were formed in A) High agitation, 200 rpm for 5 minutes in water B) Moderate agitation, 100 
rpm for 5 min in ProCHO media C) or High agitation 200 rpm for 5 min in ProCHO media 
 
 The authors hypothesize that DNA and PEI molecules interact mainly through 
electrostatic interactions which have competing binding sites with charged species found in 
culture media. Intracellular proteins have been shown to displace PEI and DNA from polyplexes 
(Iida et al. 2007).35 In a similar fashion, media components likely form transitory bonds with 
polyplexes. During the incubation process, polyplexes can either form more compact complexes 
and further condense DNA, or aggregate to form larger multimeric complexes (Tros de Ilarduya 
et al. 2010).36 Aggregation of plasmids and PEI would form heterodisperse complexes. Although 
a large change in complex size with time was observed, variability at each individual time point 
was low. The trend of decreasing size of polyplexes indicates that PEI and DNA form more 
compact complexes in time. Bound media components are likely displaced by intra-polyplex 
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interactions. The time scale observed for this phenomenon was dependent on agitation and 
ranged from 10-30 minutes.  
 Forming optimal size polyplexes is an important component for a successful 
transfection. Observations from these experiments indicate mixing and agitation during the 
polyplex formation step influence polyplex size. Heterogeneities in mixing environment may 
negatively affect the formation of optimal polyplexes. Therefore, scale-up of TGE could be 
impacted by the ability to form optimal polyplexes in large bioreactors. However, the use of 
preformed complexes may alleviate this concern (Schaeger and Christensen 1999; Finsinger et 
al. 2000; Fukumoto et al. 2010; Raymond et al. 2011; Fliedl and Kaisermayer 2011; Jang et al. 
2006). 
 
2.3.2 Cell density effect on transfection 
 In order to experimentally investigate the transfection process, 125-ml shaker flasks 
were transfected with variable cell densities. Cell density at transfection was tested at 25 *106 
cells/ml, 12.5 *106 cells/ml, and 6.25 *106 cells/ml. Each culture was transfected under similar 
conditions with the absolute concentration of PEI (100 µg/ml), and DNA (50 µg/ml) held 
constant across conditions. Transfection resulted (Figure 2.7, Table 2.3) in a linear decrease in 
integrated cell viability (IVCD) with a decrease in cell density. IVCD was a result of initial cell 
concentration, cell maintenance and growth. Transfected cells grew throughout the culture in 
the 25 *106 cells/ml treatment group, for the first three days in the 12.5 *106 cells/ml treatment 
group, and not at all in the 6.25 *106 cells/ml treatment group. Viability was similar to growth 
and had a linear increase with an increase in cell density. These viability and growth 
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observations, although limited, were consistent with a cyototoxic effect related to the number 
of polyplexes per cell. 
  Titer and Qp were however, not linearly related to cell density. Final titer of cultures was 
similar among the 6.25 and 25 transfection cultures, while there was a significant increase in 
titer in the 12.5 transfection culture. These three conditions match to the three different 
sections outlined in Figure 2.2 and demonstrate the complex window of optimal polyplexes per 
cell. From the experimental conditions tested, the best ratio was 4 µg DNA/ 106 cells and 0.5 µg 
DNA/ µg PEI. 
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Figure 2.7. Cell density effect on transfection. 
Cell mass was diluted into 25, 12.5 and 6.25 *106 cells/ml during transfection, then transfected under identical 
conditions. A) Viability B) Viable cell density and C) Final titer. Error bars represent one standard deviation (n=3). 
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Table 2.3. Cell density effect on transfection 
 
 
Culture Condition 
 
25 12.5 6.25 
Titer 53 ± 11 160 ± 89 38 ± 25 
IVCD 98 ± 37 32 ± 7.5 16 ± 9 
Qp 0.54 ± 0.11 4.9 ± 2.8 2.3 ± 1.6 
 
   
2.3.3 Agitation 
 Figure 2.5 calculated an exponential relationship to mass transport and agitation. A 
direct agitation study was conducted in shaker flasks in order to investigate the effects of 
agitation during transfection. 125-ml shaker cultures were transfected using the XLG protocol. 
Cultures were agitated at various speeds during the three hour transfection incubation period 
immediately following the addition of PEI and DNA at a temperature of 37°C. The rotating 
platform used to agitate the cultures, housed within the same incubator, ranged from 110, 150, 
180 and 210 rpms. Three hours after transfection, cultures were moved to a hypothermic 
incubator (31°C) and cultivated at 130 rpm for the remainder of the culture (8 days). These 
cultures displayed a positive correlation between agitation and volumetric productivity until the 
highest agitation condition (Figure 2.8). The viability of the 210 rpm condition after transfection 
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was very low, and too few viable cells remained for further investigation (Data not shown). It is 
important to note, that non-transfected cells cultivated under these conditions do not 
experience any cytotoxic effects, even at the highest agitation speed. Increases in rpm from 110 
to 180 could have increased the amount of DNA/cell into a more optimal range. Further 
increase in rpm to 210 could have pushed DNA/cell into the cytotoxic range. Alternatively, or in 
combination, the transfected cells could be sensitive to the hydrodynamic forces at 210 rpm. 
Although limited, these results are consistent with the optimal DNA/cell hypothesis. 
 
Figure 2.8. Agitation effect on transfection. 
CHO culture was centrifuged and resuspended in ProCHO media. DNA and PEI were directly added to cultures 
using the XLG protocol then incubated at 37°C at 110, 150, 180 or 210 rpms for three hours on a shaking platform 
before being housed in a hypothermic incubator. Titer was assayed 8 days after transfection. Error bars represent one 
standard deviation in analytical measurement (n=3). 
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2.3.4 Incubation effect on transfection 
 In order to understand the effect of transfection incubation time cells were transfected 
with identical concentration of cells, DNA and PEI but were subject to either 90 or 360 minutes 
of incubation at a temperature of 37°C. Cells were then fed a bolus of fresh medium fortified 
with 3.8 mM valproic acid after transfection and maintained at 31°C. Increases in incubation 
time lead to an increase in both cytotoxicity and specific productivity of transfected cells. 
(Figure 2.9). Cytotoxicity in the 360 minute incubation condition was 25% higher than in the 90 
minute condition, where as specific productivity was only 5% higher. Longer incubation times 
increases the amount of polyplex transport to the surface of the cell and thus internalized DNA.  
 
 
Figure 2.9. Normalized time and temperature effect on transfection.  
Cells were transfected with 20 * 106 cells/ml, 50 µg DNA/ml and 100 µg PEI/ml. Transfections were incubated for 
either 90 minutes or 360 minutes at 37°C.  
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2.3.6 Polyplex internalization 
 Once the polyplex adsorbs to the cell surface, it is internalized through ATP dependent 
protein complexes. This cellular uptake is a complicated phenomenon that includes a number 
of distinct internalization pathways (Sahay et al. 2012). Polyplexes formulated with 25 kDa PEI 
likely rely on a combination of macropinocytosis and clathrin-mediated endocytosis (Kircheis et 
al. 2001; Hufnagel et al. 2009; Wong et al. 2010; Ulasov et al. 2011). Scale-up may affect 
polyplex internalization in a number of ways. As the cell’s ability to import the polyplex is a 
function of the particles size, scale-up may affect particle formation. Moreover, endocyosis 
rates may be impacted by agitation. Polyplexes interact with the plasma membrane through 
unstable electrostatic interactions. Increases in agitation would lead to larger shear forces. 
These forces could possibly disrupt these adsportive interactions and impair internalization. The 
conflicting relationship between increased mass transfer and decreased internalization rate has 
previously been observed for cationoic lipid based gene transfer (Harris and Giorgio 2005; 
Fujiwara et al. 2006). In those studies, an applied shear stress increased the mass transfer rate 
to the surface of the cell, but destabilized the absorptive interactions between cell and lipoplex. 
Scale-up employing a constant ε (power/volume) may likely avoid inhibitory effects of increased 
dissociation of polyplexes from cell surface. 
 
2.3.7 Intracellular polyplex transport and cellular metabolism 
 Intracellular transport of polyplexes is a complicated biological process, and has been 
associated with the physiological health of the cell (Carpentier et al. 2007).46 Of most 
importance is the state of the cell in the cell cycle, as nuclear import of pDNA is enhanced 
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during mitosis (Grosjean et al. 2002; Geisse 2009).7,47 Cell metabolism during transfection is 
difficult to investigate due to the rapid time frame of gene-transfer, thus has not been studied. 
During this process, however, scale-up of agitation and aeration equipment may impact cell 
metabolism. One potential problem during scale-up is an increase in maximum shear stress, as 
the ratio of maximum local to average power dissipation increases in large bioreactors. Mixing 
regimes employed for large scale bioreactors do not produce shear forces that impair cell 
function in stable cell culture (Chisti 1993)48. Therefore, increased shear stress at larger scales is 
not likely to negatively impact cultivation of cells.   However, as PEI binds to the cell membrane, 
differences in shear sensitivity between stably transfected cells and transiently transfected cells 
may be altered. Studies on mechanisms of death in PEI mediated gene transfer indicate mainly 
the intrinsic apoptotic pathway (mitochondrial signaling) as the mechanism of post-transfection 
cell death (Beyerle et al. 2010).49 Shear forces in cell culture often induce cell death through 
other pathways (Al-Rubeai and Singh 2003)50.  Protein production machinery, have been shown 
to be altered with increasing levels of shear (Frangos et al. 1988; Senger and Karim 2003).51,52 
Investigations into the shear sensitivity of transiently transfected cells are warranted.  
 Many of the findings in the present study were not able to be explained solely through 
mass transport. They may have been impacted by factors not included in this analysis, such as 
intracellular trafficking rate, DNA replication rates, cell cycle transition rates, lysosomal activity 
rates and endocyotic machinery activities. Altered metabolism has been observed with changes 
in temperature, especially a delayed onset of apoptosis and a reduced growth rate (Moore et 
al. 1997; Rode et al. 1997; Ducommun et al. 2002).53-55 Scale-up may affect transfected-cell 
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metabolism, although the ability for large-scale bioreactors to successfully accommodate the 
demands of high-cell density, stable cultures suggest that it will not be a limiting factor.  
 
2.4 Future Work 
 Ultimately, this work has predicted the possibility of achieving large scale transfections. 
In order to scale transfection, transport of polyplexes from the medium to the cell should be 
taken into consideration. This includes an optimum number of plasmids entering into each cell, 
which is a function of cell concentration, cell/PEI/DNA ratio and agitation. Additional work may 
entail investigation into transfection with incubation times less than 90 minutes, which may 
demonstrate mass transport limitations in shaker flasks. In addition, pilot scale studies should 
be conducted to investigate the validity of these findings and generate protocols for rapid 
production of very large quantities of recombinant protein.  
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CHAPTER 3. OPTIMAL TRANSIENT GENE EXPRESSION 
SYSTEMS FOR LARGE-SCALE PRODUCTION OF 
ANTIBODIES  
 
Abstract 
Transient gene expression in mammalian culture is a potential solution for rapid production of 
recombinant proteins. The polycation polyethylenimine is a widely used reagent for milligram 
to gram scale transfections as it is simple to use, cost effective, and provides relatively high 
titers. As with most transfection reagents, PEI-mediated transfection involves the formation of 
nanoparticles (polyplexes) which are obtained by its mixing with plasmid DNA. As the quality of 
polyplexes, physiological condition of the cells, and cultivation method directly impact 
transfection efficiency and productivity, formation of scalable processes is difficult. This study 
sought to understand some of the factors in TGE processes that give rise to process variability 
and generate an optimized TGE protocol. The final method included the use of CHO-S cells in 
ProCHO5 media using an αIl-8 antibody. In addition, this process was implemented into a 
scalable system using tangential flow filtration (TFF) for cell concentration and medium 
exchange. This allowed transfection to occur in the same bioreactor as inoculum expansion. 
Moreover, TFF bioreactors provided the highest titer reported in CHO-TGE cultures.  
 
3.1 Introduction 
 The introduction of foreign genetic material into cultured eukaryotic cells without 
selection for stable integration of plasmids into the host genome has become a standard 
experimental procedure known as transient gene expression (TGE). For decades, transfections 
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have been performed in cell biology labs on a small scale basis to analyze the effect of 
gene/protein perturbation and their effects on biological systems (Geisse 2009). TGE has 
allowed the production of small amounts of recombinant protein, often in crude supernatants 
and without sophisticated purification. This approach offers many advantages for researchers 
as it is rapid, simple and can be applied to a multitude of cell lines (Geisse and Fux 2009).  
 The first TGE approaches predominantly employed Human Embryonic Kidney-293 (HEK-
293) cells as the host cell line. More recently, large scale transient transfection protocols have 
also been established for Chinese Hamster Ovary (CHO) cells (Baldi et al. 2005; Jordan et al. 
1998; Pham et al. 2003; Shi et al. 2005; Baldi et al. 2007). Due to their human like post-
translational modifications, CHO cells are the most commonly used expression host for 
biopharmaceutical production (Wurm 2004). Transient based CHO processes provide milligram 
to gram quantities of recombinant protein within weeks. This is in contrast to conventional 
approaches of generating stable cell lines that takes several months to develop (Wurm and 
Bernard 1999; Pham et al. 2006) 
 Polyethlenimine (PEI) is a cationic polymer used in gene transfer for a number of years 
(Boussif et al. 1995). PEI is available in various configurations, however, 25 kDa linear PEI has 
been shown to be the best molecular weight and structure for TGE found to date (Bertschinger 
et al. 2008; Kopatz et al. 2004; Godbey et al. 1999). With a high cationic charge density, PEI 
condenses DNA to form a compact, positively-charged particle. This complex is endocytosed, 
and escapes endosomal vesicles through the proton-sponge effect. Basic nitrogen atoms 
become protonated and cause an influx of chloride ions which rupture the vesicle through 
osmotic swelling (Akinc et al. 2005; Thomas and Klibanov 2003). Plasmid DNA then travels to 
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the nucleus where it is transcribed. How nuclear translocation of polyplexes occurs is not well 
characterized. As reported for other transfection agents, transnucleation is believed to be one 
of the major obstacles to high transfection efficiency (Carpentier et al. 2007; Bieber et al. 2002; 
Brunner et al. 2002; Escriou et al. 2001). 
 While transfection protocols have yet to be standardized, many studies have looked at 
increasing the effectiveness of transfection through increasing the number of cells expressing 
the gene (transfection efficiency) as well as the cell’s specific productivity. Many factors 
involved in the transfection process have been studied, including cell/DNA/PEI ratios, yet there 
still remain significant gaps in the process understanding and optimization of transfection 
methods. One goal of this work was to identify an optimal system for r-protein production using 
off the shelf reagents. 
 In addition to a high titer, the TGE process developed in this work required scalability. 
The ability to scale is vital for processes to reduce the cost of manufacture and increase 
production through scales of economy. For r- protein production by TGE, scales up to hundreds 
of liters have been successfully employed at commercial firms to produce research material. 
Most methods employed at these larger scales utilize low cell density cultures with no cell 
concentration or medium exchange employed as part of the transfection step. These processes 
do not require sterile cell-liquid separation, yet suffer from low titers. High titer processes, 
however, utilize high density cultures with cell concentration and medium exchange steps prior 
to transfection. All such protocols published to date, utilize external batch centrifugation, using 
lab-scale centrifuges, for media exchange and cell concentration (Wulhfard et al. 2008; Pham et 
al. 2006; Girard et al. 2002; Tuvesson et al. 2008). This method is typically limited in scale to 20 
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liters or less, as cells are typically processed in batches of 6-L or less (i.e, 6 x 1-L bottles). There 
are a number of mammalian cell retention techniques for large scale cultures which have yet to 
be tested for transfection processes, including gravity settlers, tangential flow filters, acoustic 
filters, and hydrocyclones (Scheirer, 1988; Tokashiki and Takamatsu, 1993; Woodside et al., 
1998; Castilho and Medronho, 2002). The goal of this work was to create an optimal TGE 
process that can demonstrate scalability to larger bioreactors.   
 
3.2 Materials and methods 
3.2.1 Plasmid constructs 
Two plasmids were used in this study. The first, referred to here after as αIl-8, was 
p6G4V11N35E.choSD.10 (ATCC HB-11722), designed to coexpress variable light and heavy 
regions of the murine 6G4.2.5 monoclonal antibody with human constant regions. The second, 
referred to hereafter as pSEAP-Fc, was pFUSE-SEAP-hIgG1-Fc (InVivogen, Carlsbad, CA) which 
encodes for a secreted alkaline phosphatase moiety fused to a human IgG1-Fc backbone. 
Plasmids were either purchased (Nature Technology Corporation, Lincoln NA) or produced in 
Escherichia coli strain DH5α grown in Luria broth medium containing appropriate antibiotic. 
Plasmid DNA was isolated and purified using Giga-Prep kit (Qiagen) according to the 
manufacturer’s protocol. 
3.2.2 Cell culture 
Experiments were performed with three different CHO cell lines. (1) CHO-K1 (ATCC: CCL-61), a 
parental CHO line  (Puck et al. 1958); (2) DG44 ( Life Technologies, Hercules, CA), a dhfr- CHO 
line (Urlaub and Chasin 1980)  that is pre-adapted to suspension culture and is frequently used 
in industry for stable gene expression (SGE) and (3) CHO-S (Life Technologies), a CHO line 
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derived from CHO-K1 that is pre-adapted to chemically defined, suspension culture  (Deaven & 
Petersen 1973; D'Anna 1996; D'Anna et al. 1997). CHO-K1 cells were cultured for at least one 
passage adhered to a T-flask (Corning). The cells were removed from the flask surface through 
trypsinization, placed in suspension culture in a shaker flask and subsequently grown in 
suspension culture. All cells were initially grown in DG44 media (Life Technologies), then 
cultured in either chemically defined ProCHO5 media (Lonza) supplemented with 4.1 mM L-
glutamine, HT supplement (Life Technologies) or OptiCHO media (Life Technologies) 
supplemented with 8mM L-glutamine. Cells were passaged every 3-4 days at densities ranging 
from 0.3*106 cells/ml to 5.0 *106 cells/ml (more dense passaging was used for scale-up). Cells 
were cultivated in 125 ml shaker flasks (Corning) operated at 30 mls of culture volume, placed 
in a large, humidified incubator (Thermofisher) at 37⁰C, 8% CO2. The shaker cultures were 
agitated on a rotary shaker (New Brunswick) at 130 rpm. 
3.2.3 Transfections in shaker flasks 
Transfections were a modified version of the XLG protocol (Backliwal et al. 2009). Cells were 
centrifuged prior to transfection and resuspended at a cell density of 20*106 cells/ml in 
ProCHO5 media. DNA was added to a final concentration of 50 µg/ml directly to the cells. This 
was immediately followed by addition of the appropriate amount of a 1 mg/ml solution of 25-
kDa polyethyleneimine (PEI; Polysciences) to a final concentration of 100 µg/ml. Four hours 
after transfection, cells were diluted with media to a cell density of 4*106  cells/ml, and valproic 
acid (VPA, Sigma-Aldrich) was added to a final concentration of 3.8 mmol/l. Cultures were 
performed in triplicate and maintained with agitation at 31°C for up to 10 days with 30 ml final 
volume after dilution in a 125 ml shaker flask (Corning). 
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3.2.4 Transfection in bioreactors 
Bioreactor transfections used the same Cell/DNA/PEI ratio as small scale. Cells were grown in 
either 1- or 3-L bioreactors (Applikon, Foster City, CA) in ProCHO5 media. Cells were maintained 
below 5 *106 cells/ml in order to ensure exponential growth. Cultures were maintained at set 
points 37°C, 200 rpm, pH of 7.08, and dissolved oxygen (DO) of 40% air saturation. Agitation 
was at 200 rpm using the standard 3-bladed Applikon pitched-blade impeller. pH was 
maintained through addition of CO2 sparged gas or 1N sodium bicarbonate (VWR). Dissolved 
oxygen levels were maintained through sparging with air, and if needed oxygen. Once sufficient 
cell mass was generated, cell were concentrated either through external centrifugation, 
acoustic perfusion, or tangential flow filtration. Satellite cultures were periodically pulled from 
the bioreactor aseptically then subsequently maintained as shaker cultures. Transfections were 
conducted using the same ratio of cell/DNA/PEI as shaker flask transfections. Transfected cells 
were maintained in the bioreactor at 31°C, 200 rpm, pH of 7.08, and DO of 40% air saturation.  
3.2.5 Cell separation techniques 
3.2.5.1 Centrifugation  
 For centrifugation, cell suspension was centrifuged at 3k rpm for 8 min on a 5682 Benchtop 
Centrifuge (Forma), then resuspended in an appropriate volume of media.  
3.2.5.2 Acoustic perfusion 
Cells were separated from media by acoustic perfusion using a BioSep 10L system (AppliSens, 
Applikon). Operating parameters were 1 min/ 3 secs of operation/back-flush, respectively, at 
the highest frequency possible. The percentage separation efficiency (SE) was calculated based 
on the ratio of the cell concentrations in the outflow and reactor, i.e., SE = 100 * (Xvr –Xvp) /Xvr   
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where SE is the separation efficiency (%), Xvr is the viable cell concentration in the bioreactor  
and Xvp is the viable-cell concentration in the perfusion flow. 
3.2.5.3 Filtration 
Cell suspension was concentrated through filtration using a tangential flow filter (TFF). This 
consisted of a 100 kDa MWCO hollow fiber (GE) operated with peristaltic pumps (Masterflex) at 
75 ml/m2* min. 
 
3.2.6 Cell, protein and metabolite analysis 
Viable cell density (VCD), viability, and cell size were determined using a Beckman Coulter Vi-
Cell Viability Analyzer (Beckman Coulter). Lactate, ammonia, glucose, glutamine, glutamate, 
and pH were monitored using a Nova Biomedical Bioprofile 400 Analyzer (Nova Biomedical). 
Osmolality was measured using a micro osmometer (Advanced Instruments). Supernatant 
samples were centrifuged, then stored at −80°C for further analysis. Specific growth rate (μ), in 
doublings per day, was calculated as change in VCD over a time interval t1 to t2 (Equation 1.) 
L = ;<(DE DE9⁄ )8&89  (1) 
The IgG concentration in the culture medium was determined by sandwich ELISA as previously 
described (Meissner et al. 2001; Pick et al. 2002). In short, goat anti-human Fc (Sigma, St. Louis, 
MN) was used for coating the ELISA - plates, and the synthesized IgG fusion protein was 
detected with Horse Radish Peroxidase (HRP)-conjugated goat anti-human IgG-Fc (Sigma). OPD 
was used as a substrate for the HRP. Absorption was measured at 450 nm using a microplate 
reader (SPECTRAmax340; BioRad, Herceles, CA). 
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3.3 Results and discussion 
3.3.1 Protein specific variability  
 In order to create a model system for TGE, differences in protein expression were 
investigated. Measuring differences in protein expression are important to understand the 
inherent biological variability in a TGE process.  For this effort, two plasmids of similar sizes that 
encode for IgG1 antibodies were testing in shaker cultures. One antibody targets the 
interleukin-8 (IL-8) protein while the other antibody is a SEAP fusion protein with a human Fc 
domain (pSEAP-Fc). Transfections were conducted holding all variables as similar as possible 
except for the particularly plasmid gene sequence.  The change in gene sequence resulted in 
significantly different amounts of protein produced between the two conditions (Figure 3.1, 
Table 3.1). Upon harvest, there was a 14-fold difference in volumetric productivity of these 
proteins (p<0.01). There was also a log difference in specific productivity between the two 
proteins.   The IVCD values differed by less than 50%, indicating the protein specific expression 
rather than the number of expression cells elicited the observed differences.  
 
Figure 3.1. Protein specific variability on TGE. 
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Shaker flask transfections of CHO-K1 using PEI and various DNA at similar ratios. Error bars represent one standard 
deviation (n=3) 
 
Table 3.1. Protein specific TGE variability 
  Titer IVCD Qp 
αIl-8 39.77 31.89 1.27 
SEAP 2.76 22.84 0.12 
 
 
 These observations are supported by other studies (Durocher et al. 2002; Girard et al. 
2002; Baldi et al. 2005), which found protein expression levels varied between 1 and 20 mg/L at 
time of harvest (9 days) in 3-14 L bioreactors, using the same plasmid and transfection protocol. 
Moreover, fusion proteins have been found to often express with lower titers than standard 
IgGs (Suen et al. 2010; Cheng 2011). The observed protein specific variability found in this study 
indicates a novel protein may not express as well as model proteins or other antibodies. 
Nevertheless, improvements may be able to reduce this variability, such as the development of 
a specially designed plasmid for transient transfection. Such materials are currently being 
investigated (Durocher et al. 2002; Geisse and Henke 2005). Furthermore, the primary goal of 
this work centers on antibody production for immunotherapy. 
 
3.3.2 Cell-line and media variability 
 In order to create a more efficient TGE process, cell line and media formulation were 
experimentally optimized. To investigate the specific CHO cell line and media effect on 
transfection, three similar CHO cell lines, CHO-S, CHO-K1 and DG44, were tested in a media 
formulated for transfection (ProCHO) as well as a richer growth media, OptiCHO.  Transfections 
varied among cell lines and media formulations (Figure 3.2). A more minimal, ProCHO 
transfection media was universally more productive than the richer growth media for 
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transfections. CHO-S was the most productive cell line, followed by CHO-K1 and DG44. DG44 
was below the limit of quantification on the ELISA assay, but was above the limit of detection, 
indicating protein was expressed but at a very low level. 
 
Figure 3.2. Cell and media effects on TGE performance.   
CHO-S (S); CHO-K1 (K) and DG44 (DG44) were transfected in ProCHO media (Pro) or OptiCHO media (Opti) 
and titer was assessed on day 4. 
 
 
 Only in recent years have attempts to use CHO cells as hosts for transient transfection 
processes emerged. A number of CHO cell lines have been employed, derived from either CHO 
K1 wild-type cells or the DHFR-negative variants DG44 and DUKX-B11 (Gottesman 1987; Kao 
and Puck 1968; Urlaub 1980; Urlaub 1983). CHO cells have been described as prone to 
genotypic aberrations, and for the DG44 strain a genetic characterization has been recently 
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performed in support of this view (Derouazi et al. 2006). Thus, it must be assumed that the 
different CHO strains in use in various laboratories may differ considerably in genotype as well 
as in behavior. Consistent with these studies, cell lines exhibited significant differences in 
expression in this study. Cell line differences could speculatively be related to either a lower 
cellular uptake of plasmid DNA, reduced nuclear import or lack of metabolic machinery to 
enhance expression. DG44, which lack the DHFR gene, exhibited the lowest titer of all cell lines. 
This metabolic disadvantage may have decreased this cell line’s ability to express the protein 
transiently compared to other cell lines. The optimal system derived from these experiments 
includes the use of FreeStyle CHO-S cells in ProCHO5 media.  
 
3.3.3 Aseptic liquid-cell separation techniques 
 Results from the media study indicate that ProCHO5 was the optimal transfection 
media. This advantage is in contrast to OptiCHO’s favorable ability to support higher cell 
densities. An ideal process would expand inoculum in a growth-favorable media, then exchange 
the media to a more transfection-favorable one, such as ProCHO5. High titer processes often 
use this strategy but typically conduct these operations using batch centrifugation. This method 
does not scale above 10’s of liters. In order to develop more scalable systems for media 
exchange, a number of aseptic liquid-cell separation techniques were tested. These included an 
acoustic perfusion system and a tangential flow filtration system for transfection in 3-L 
bioreactors. 
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3.3.3.1 Acoustic perfusion 
 Acoustic perfusion for media exchange in a 3-L bioreactor was not ideal. This was mainly 
due to the system having less than 50% separation efficiency during inocoulum expansion 
(Figure 3.3). This was likely due to gas bubble nucleation, growth, and release within the uptake 
line, resulting in disruption of cell capture by the acoustic filter. These results are similar for 
non-optimized systems reported in the literature (Woodside et al. 1998; Crowley et al. 2003; 
Gorenflo et al. 2005). While optimization of the acoustic system was possible, capacity 
limitations with this technology (upper limit of approximately 200 to 2000-L bioreactors; 
Voisard et al. 2003) motivated investigation in a different direction.  
 
Figure 3.3. Acoustic filtration performance.  
Culture was grown in a 3-L bioreactor. Once cells reached 4*106 cells/ ml (time=0), the filter 
was turned on and maintained for a 24 hour period.  
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3.3.3.2 Tangential flow filtration 
 To evaluate the use of a TFF system, filtration induced cell damage had to first be 
assessed. A 3-L bioreactor was equipped with an autoclavable hollow fiber TFF system. 
Inoculum culture was expanded then filtered through the hollow fiber. Satellite cultures were 
pulled from the reactor before filtration began, after 4 hours of filtration, after 8 hours of 
filtration and after 12 hours of filtration. Satellite cultures were diluted to a similar density 
using spent media that was collected either from the bioreactor before filtration began (Hour 0, 
4, 8) or from the permeate line (Hour 12). Satellite cultures were maintained in shaker flasks for 
6 days and damage from filtration was assessed through the specific growth rate of the 
cultivated cells. If cell damage occurred, specific growth rates would have been consistently 
lower as filtration continued. This effect was not observed from the cultures pulled throughout 
operation (Figure 3.4), thus filtration did not induce cell damage. Differences between the 
various treatment groups were more likely a result of pipetting and analytical error rather than 
biologically significance.  
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Figure 3.4. Assessment of damage resulting from TFF operations.  
Expanded inoculum was filtered using an inline TFF system. Satellite cultures were pulled before operations began 
(black), 4 hours of filtration (white), 8 hours of filtration (checkered), and after 12 hours of filtration (grey). Cultures 
were diluted with spent media to a low density to allow cell growth. Specific growth rates were calculated using 
Equation  1.  
 
 Before the TFF system could be used for transfections, the amount of media exchange 
required to enable highly efficient processes was necessary. This effort was conducted by 
transfecting cells in fresh media, spent media and a 50-50 mixture of the two. Inoculum was 
expanded in 3-L bioreactor. Cells and spend media were removed on day 3 and separated 
through centrifugation. Cells were resuspended in the various media compositions then 
transfected in shaker flasks. There was a significant difference in titer for conditioned media 
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(p<0.01), while such a trend was not observed in the 50-50 case (Figure 3.5). These experiments 
indicate that a simple 2x concentration step using filtration, prior to transfection, followed by 
dilution with fresh medium back up to the original volume, after transfection, may be sufficient 
to enable high volumetric productivity processes. 
 
 
Figure 3.5. Conditioned media effect on transfections.  
Transfections were carried out in 125 ml shaker flasks with fresh media, conditioned media or a 50-50 mix of the 
two. Error bars represent one standard deviation of the mean (n=3) 
 
 
 This study found that media formulation significantly affected protein concentration at 
harvest. This is consistent with previous studies, which have examined a diverse set of media 
formulations (Codamo et al. 2010).  In addition, these experiments observed the use of 100% 
conditioned media during transfection resulted in a reduced titer. This observation is also 
consistent with reported studies in literature (Schlaeger and Christensen 1999; Tuvesson et al. 
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2008). Previous studies found that the use of 25% or more conditioned media in low-cell-
density resulted in reduced protein concentrations 72 hours post-transfection.  The high-cell-
density system in these experiments demonstrate up to 50% conditioned medium could be 
used without negatively impacting titer. 
 Media’s influence on transfection is thought to be attributed to the cellular debris 
accumulation due to cell death, charged species secreted by viable cells, and charged 
components within the basal media. Cells produce autocrine factors that can have an influence 
on cell growth (Ozturk and Palsson 1990) and glycosaminoglycans (GAG’s) that facilitate cell-cell 
communication. These molecules accumulate in the medium and it is believed that they might 
interfere with the transfection process. GAG’s in particular, are anionic-polysaccharides 
commonly found linked to extracellular matrix proteins, so called proteoglycans (PG’s), and 
perform vital roles in cell signaling and cell-cell communication (Linhardt and Toida 2004). 
Cationic lipid-mediated gene transfer has been found to be inhibited by secreted cellular 
proteins, in particular PG’s (Belting and Petersson 1999). PG’s form complexes with cationic 
lipids/DNA particles, leading to the release of DNA and intracellular accumulation of lipid-PG 
complexes. This results in inhibition of DNA uptake and a significant reduction in reporter-gene 
expression (Belting and Petersson 1999; Belting et al. 2005; Gardner et al. 2007). These findings 
support the observation that use of high levels of conditioned medium can have a negative 
effect on protein expression. 
 This study also found that 50% conditioned media did not significantly reduce protein 
levels. Tuvesson et al. (2008) found that the use of more than 25% conditioned media during 
transfections impairs transfections. These studies however used low density transfections. 
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Therefore the concentration of inhibiting species during transfections in this study was likely 
not high enough to significantly impair transfection. The use of 50% conditioned media, or a 1x 
media exchange was found to be sufficient to remove inhibiting components within the media.  
 The use of rich media, however, has the advantage of supporting high density cultures. 
Production media in commercial cell culture often can support cell densities in the tens of 
millions of cells per ml. ProCHO5, however, is only able to support 5*106 cells per ml, and is not 
ideal for production culture.  
 
3.3.4 Filtration 
 To test the ability for TFF to aseptically separate cells from liquid prior to transfection, a 
modified 3-L bioreactor was fitted with an inline 100 kDa MWCO hollow fiber unit. Inoculum 
was expanded in the 3-L bioreactor. When sufficient cell mass was generated, satellite cultures 
were pulled, centrifuged, resuspended, then transfected and grown in shaker flasks (Cen/Shake 
set). Subsequent to pulling of the satellite cultures for Cen/Shake set, cross-flow filtration of the 
cells in the bioreactor was initialized and cells were concentrated 2.5x without loss in viability 
and a high separation efficiency (<98%). Cells were then fed 2 volumes of fresh media and 
concentrated down to transfection density. Satellite cultures were pulled from the bioreactor 
and then transfected and maintained in shaker flasks (Fil/Shake set). Cells remaining in the 
bioreactor were transfected and subsequently maintained in the bioreactor (Reactor set). After 
cells were fed, satellite cultures from the bioreactor were pulled and cultivated in a shaker flask 
(Reactor/Shaker set). Transfection results are shown in Figure 3.6 and Table 3.2. The shaker 
transfected cultures had significantly lower viability compared to the cultures transfected in the 
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bioreactor. In addition, the centrifuged cultures had significantly lower viability compared to 
other treatment groups. VCD and IVCD demonstrated similar trends, indicating transfections in 
shaker flasks were more cytotoxic than in the bioreactor. In addition, the bioreactor maintained 
a higher viable-cell-mass than any other culture (IVCD of 68.3). Titer was similar among the 
centrifuged and filtered cells, indicating TFF as a separation technique was successful. Titer 
differences were significant between the shaker transfected cells and the bioreactor cells 
maintained in the shaker flask (p<0.01). The reactor, on the other hand had the highest titer 
with 304 mg/L. Specific productivity varied over 4 fold between the cultures, where the 
centrifuged culture had the highest Qp of 10.7 pg/cell day. The lowest Qp was the 
Reactor/Shaker set (2.78 pg/cell day).  
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Figure 3.6. Transfection of cells using scalable unit operations.  
 A) Viability of the transfections  B)Viable cell density of the transfections. Error bars represent one standard 
deviation of the mean (n=3), except for the reactor condition which was a single culture. 
 
 
Table 3.2. Transfection of cells using scalable unit operations  
  IVCD Titer Qp 
Cen/Shake 24.1 ± 4.3 258 ± 16 10.7 ± 0.6 
Fil/Shake 56.0 ± 7.0 255 ± 12 4.55 ± 0.5 
Reactor/Shake 65.7 ± 6.5 183 ± 17 2.78 ± 0.6 
Reactor 68.3 304 4.45 
 
 
3.4 Conclusion 
This study sought to generate an optimal transfection protocol using CHO cells that could 
potentially scale to the 000’s of liter scale. Many groups have investigated the variables 
involved in the transfection process to identify high titer TGE processes (Figure 3.7; Elouahabi 
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and Ruysschaert 2005; Godbey et al. 1999; Galbraith et al. 2006; Tait et al. 2004; Bertschinger 
et al. 2008).  
 
 
 
Figure 3.7. Fish bone diagram of the variables involved in TGE. 
 
This work investigated a novel set of variables to generate an optimized TGE protocol. 
The final method included the use of CHO-S cells in ProCHO5 media using an αIl-8 antibody. In 
addition, this process was implemented into a scalable system using TFF that allowed 
transfection to occur in the same bioreactor as inoculum expansion. This process may provide a 
superior alternative as the operational complexity is dramatically reduced. Moreover, TFF 
bioreactors provided the highest titer reported in CHO-TGE cultures (Figure 3.8). 
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Figure 3.8. Comparison of reported CHO-TGE culture titers. 
Shown in black are cultures conducted here at KGI, whereas the blue cultures are found in the literature. Note; 
Outside of this work, Rajendra et al. 2011 has the highest reported titer (250 mg/L) for CHO based TGE cultures 
greater than 30 mls.  
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CHAPTER 4. PROCESSES SIMULATION FOR LARGE-SCALE 
TRANSIENT GENE EXPRESSION  
 
Abstract  
Rapid, large scale production of monoclonal antibodies is necessary for bio-defense needs. 
Current production systems do not fulfill this need as they suffer from either not producing 
satisfactory high-quality antibodies, or not producing antibodies within a relevant timeline. One 
solution to this unmet medical need is the use transient gene expression in Chinese hamster 
ovary (CHO) cell culture, utilizing large scale industrial bioreactors. In this study, we aimed to 
assess the feasibility of such an approach through process simulation. SuperPro flow sheets 
were generated representing the most up to date methods in transient antibody production. 
After calibration of key parameters, the model calculated a facility with 200,000-L bioreactor 
capacity and would produce between 32 and 1,274 kg of high-quality antibody within 12 weeks. 
Production output was primarily dependent on volumetric productivity. Similarly, cost of 
manufacturing recombinant protein was dependent on volumetric productivity, and was $164 
per gram for a process that would meet bio-defense needs of 1,200 kg. Increases beyond 500 
mg/L in volumetric productivity provided marginal reductions in the cost of production. Lab 
scale bioreactor studies provided better parameter estimates, which were used to refine large 
scale simulation. Results of this work demonstrate the feasibility of meeting bio-defense needs 
through the use of large-scale, transient gene expression.  
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4.1 Introduction 
 The production of recombinant proteins (r-proteins) is an emerging technology with a 
central focus on medical applications. Many therapeutic biopharmaceutical r-proteins are 
complex molecules that need to be post-translationally modified for full bioactivity, especially 
monoclonal antibodies (mAbs). These modifications are performed optimally by mammalian 
cell culture, especially Chinese hamster ovary (CHO) cells (Wurm 2004). Pharmaceutical 
companies routinely establish stable recombinant cell lines that predictably produce r-proteins 
for extended cultivation times. This form of production, often called stable gene expression 
(SGE), is achieved through the insertion of recombinant genes into the host genome. 
Identification and characterization of these cell lines is, however, a costly and time-consuming 
process (Baldi et al. 2007). Faster approaches to r-protein production are necessary for rapid 
production capabilities, such as passive antibody administration for use in mass-casualty 
biological catastrophes (Casadevall 2002; DARPA 2006; Tether 2010).  
 The bio-defense market has previously been described in detail (Chapter 1). Briefly, the 
Defense Advanced Research Program Agency (DARPA) describes three milestones for bio-
defense production capability. These are 12, 120 and 1,200 kg of high-quality, monoclonal 
antibody produced within a three month window (DARPA 2006). Transient gene expression 
(TGE) is well-suited to fill this need. In contrast to stable gene expression, TGE involves short-
term r-protein production typically for up to 14 days post-transfection in the absence of genetic 
selection of the plasmid DNA.  Recent advances in TGE have successfully provided high-titer 
production processes (gram/L) at smaller scales (<10 L) (Backliwal et al. 2008; Geisse and Fux 
2009; Hacker et al. 2010). For mass casualty events where medical countermeasures are 
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needed, these systems could potentially be scaled to industrial size bioreactors (25,000 L) to 
produce significant amounts of antibody based medical countermeasures. Because of idle 
capacity within the biomanufacturing industry (Levine 2010), this scenario may become a 
reality. A better understanding of the possible output of such a large scale production process 
would provide greater incentive for investment from both public and private sector 
stakeholders.  
In order to do this modeling, process simulation was conducted based off of current TGE 
processes in SuperPro Designer software to elucidate this possibility. Process simulation allows 
for advanced forecasting, planning and comparison of various processes and facilities under a 
range of different production levels, cost structures and process efficiencies (Simpson 2011). 
Utilizing process simulation, the goal of this work is to characterize the potential of a large scale 
TGE processes to fulfill the needs of bio-defense in the event of a biological catastrophe.  
 
4.2 Model  
 Many commercial antibodies are manufactured using similar processes (Farid 2001; 
Wurm 2004; Sommerfeld and Strube 2005; Farid 2006; Birch et al. 2006); the majority use 
batch/fed-batch mammalian cell culture followed by purification steps that rely primarily on 
chromatography with intermediate filtration and viral clearance operations (Figure 4.1A). TGE 
methods utilize similar unit operations (Tuvesson et al. 2008; Geisse and Fux 2009) with the 
addition of a cell concentration and medium exchange step (Figure 4.1B). 
A 
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Figure 4.1. Process flow diagram for mAb production with SGE and TGE 
SGE is shown in A and TGE is shown in B. Molecular biology operations are shaded in green, while commercial 
manufacturing operations are shaded yellow. Differences between stable and transient gene expression processes are 
shaded red.  
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4.2.1 Building a model  
 A deterministic flow sheet containing a schematic representation of all unit operations 
that must be performed to convert raw materials into final antibody product was generated 
using SuperPro Designer version 7.0 (Intelligen). This flow sheet (Figure 4.2) is an adaptation 
from previously reported models (Heinzle et al. 2006; Harrison et al. 2006; Abramzon and 
Croughan 2007). Although the size of the equipment has changed to represent a 25,000 L cell 
culture process, the sequence of unit operations remains unaltered. This model includes cell 
culture, primary recovery, protein-A capture, chemical virus inactivation, purification through 
anionic exchange column chromatography and hydrophobic interaction chromatography, viral 
exclusion, and fill finish operations. For a detailed description of unit operations and their 
parameters, see Appendix.  
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4.2.2 Calibrating the model 
 After creating the flow sheet, the model must be calibrated to represent realistic costs, 
cycle times and yields. Two key parameters to calibrate model output were capital investment 
required to build or acquire the plant and the cost of manufacturing r-proteins. Capital 
investment refers to the cost for the facilities which house the manufacturing equipment as 
well as the large, fixed asset, items used during the manufacturing process. Benchmarks for cell 
culture capital investment can be found in literature as well as anecdotal report from 
biomanufacturing professionals (Table 4.1; Fraid 2006).  
 
 
Table 4.1.  Capital investment costs for cell culture facilities producing antibodies 
 Adapted from Farid 2006 
Manufacturing Facility 
Date facility 
completed 
Capital 
investment 
(US $M) 
Area (ft
2
) Production bioreactor capacity 
        Number 
Size 
(000’s L) 
Total 
(000’s L) 
Genentech- Vacaville, CA, USA 2000 250 310000 8 12 96 
Imclone- Branchburg BB36, NJ, USA 2001 53 80000 3 10 30 
Abiogen- LSM, RTP, NC, USA 2001 175 245000 6 15 90 
Boehringer Ingelheim expansion- Biberach, Germany 2003 315 na 6 15 90 
Lonza biologics expansion- Portsmouth, NH, USA 2004 207 270000 3 20 60 
Amgen- BioNext, West Greenwich, RI, USA 2005 500 500000 9 20 180 
Genentech- NIMO- Oceanside, CA, USA 2005 380 470000 6 15 90 
Imclone- Branchburg BB50, NJ, USA 2005 260 250000 9 11 99 
Biogen Idec- Hillerod, Denmark 2007 350 366000 6 15 90 
Lonza biologics- Tuas, Singapore 2009 250 na 4 20 80 
Genentech expansion- Vacaville, CA, USA 2009 600 380000 8 25 200 
 
 
From the reported costs in Table 4.1, it is possible to derive benchmark investment costs 
relative to bioreactor capacity of $250,000-$500,000 per 1000- liter. This data, as Farid notes 
(2006), is a ball-park figure with certain limitations. It is not always clear whether the reported 
costs include indirect expenses such as warehouses, support facilities and office areas and 
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validation. For a baseline, a plant with 200,000 L production bioreactor capacity was modeled 
at $600 M, or the original price of Genentech’s expansion plant (CCPII). Two alternative 
scenarios exists which would either increase or decrease the cost of the facility. In one scenario, 
purchasing of idle capacity would significantly reduce the capital cost, potentially at a cost next 
to nothing, or donation. This scenario is realistic due to tax incentives of donating idle capacity. 
The cost of retro-fitting a facility that was acquired via donation would be significantly lower 
than the original purchase price. For this scenario, the total cost of the plant was modeled at 
$100M. In the second scenario, such as building an entirely new plant, would have a cost higher 
than the 2009 price due to inflation and rising costs for bio-manufacturing construction. For this 
scenario, the fixed costs were modeled as $1000M. 
 
3.2.2.1 COGM 
 Another critical factor for model calibration is the cost of goods manufactured (COGM). 
COGM is a function of the facility size and efficiency of the process, which includes all relevant 
variable and fixed costs associate with production. Commercial antibody manufacture in the 
250 kg/year scale produces drug substance (not vialed), around $100-$300 per gram (Kelly 
2009). Other studies indicate that processes employing larger scales would reduce COGM down 
to potentially $20/ gram (Kelly 2007; Werner et al. 2004). This estimate is low compared to 
actual costs of commercial antibody production for a number of reasons. First, vialing adds a 
substantial portion of costs, between $25-$250/gram, depending on the final product 
configuration. Second, quality systems, distribution and supply chain costs, and the cost of 
auxiliary operational functions are not included in these cost estimates. Further issues that 
complicate cost comparisons are whether the COGM values quoted in publicly available 
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documents include formulation steps, and whether they are for single-product dedicated 
facilities or for multi-product facilities. It is difficult to accurately assess these costs and out of 
scope of this work. To simplify cost benchmarking for the base-case of this model, which utilizes 
200,000 L of capacity and a titer of 1 gm/L, a conservative estimate of $200 /g was adopted.  
 
4.2.2.2 Base-case assumptions 
COGM and capital cost metrics were used to generate a model with known production outputs. 
These processes fixed costs for labor, QA/QC tests, raw materials, and consumables for all 
subsequent models. This baseline facility was then manipulated to simulate a TGE process. The 
resulting TGE process maintained a number of assumptions for the base-case, which are 
summarized in Table 4.2. These include: (1) The mAb product is secreted by suspension 
adapted CHO cells which are grown in 25,000-L stainless steel, stirred tank bioreactors; (2) 
Production bioreactor operations include a 9 day fermentation, one day of to harvest and a two 
day turn-around time. This process ranges in volumetric productivity from 50-2000 mg/L; (3) 
Downstream yields aggregate to a 73% yield and are never the bottleneck during operation, i.e. 
there are assumed multiple purification trains if necessary; (4) The annual up-time for the plant 
is 3 months /year with a 95% utilization rate; (5) Fixed costs for the 200,000-L capacity are $600 
million, depreciation was either included using a straight line method, or excluded; (6) There is 
a 5% overall process failure rate; (7) The specific growth rate (µ) for CHO is 18 hours, which has 
been experimentally validated (data not shown); (8) Cost of DNA is $377/gram and is always 
available on demand (see chapter 5 for details); (9) PEI is $30/gram and always available. 
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Table 4.2. Base-case assumptions 
Production System CHO in stirred tank 
bioreactors 
Bioreactor 
Fermentation  
9 days 
Bioreactor Harvest 1 day 
Bioreactor Turn-
around  
2 days 
Downstream Yield 73% 
Plant Capacity 200,000 (8x 25,000) 
Failure Rate 5% 
Plant Uptime 3 months 
Plant Utilization 95% 
DNA $377/gram 
PEI $30/gram 
Specific Growth Rate 
(µ) 
18 hours 
Fixed Costs ($ M) $600 M 
 
 
4.2.2.3 TGE experimental validation   
To refine model parameters, TGE protocols were experimentally validated. Transfections 
(Chapter 3) were carried out in 3-L bioreactors. Results from these experiments indicate a 9 
day, PEI-based TGE process in CHO yields 304 mg/L of antibody before purification. 
 
4.3 Results 
4.3.1 Base-case 
Simulation using the base-case assumptions, outlined in Table 4.2, produced between 32 to 
1,274 kg, with a large dependency of process titer (Table 4.3, Figure 4.3). Within this set of 
processes, the bio-defense production targets of 12, 120 and 1,200 of antibody in 12 weeks 
were met with titers of 18, 190 and 1,840 mg/L, respectively. Production output increased with 
increases in titer in a linear fashion, while COGM decreased with increases in titer in an inverse 
97 
 
function. COGM displayed marginal returns at the high end of titers, starting around 500 mg/L 
(Figure 4.5). The COGM was close to $169/gram at the titers that meet the Phase 3 production 
target of 1,200 kg for countermeasures. The cost of the transfection agents compared to overall 
cost was always less than 6%. This is in disagreement with previous studies (Backliwal 2008), 
most likely due to the scales of economies utilized in this study which were not considered by 
Backliwal.   
 
Figure 4.3. Simulation results from base-case model. 
Model consisted of 8x 25,000 L reactors operating on a 12 day cycle for 3 months of operation. The process 
modeled in SuperPro v7.0 software was a PEI-mediated TGE in CHO with a range of titers. 
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Table 4.3. Antibody production targets for bio-defense 
Phase Antibody 
Required 
(kg) 
Titer 
Required 
(mg/L) 
COGM 
($/gram) 
1 12 18 35710 
2 120 188 2733 
3 1200 1883 209 
 
4.3.2 Experimental validation 
In order to corroborate some of the parameters that were used during simulation (Table 4.2), 
especially titer, CHO transfections using PEI were conducted in 3-L bioreactors (Chapter 3). 
Transfections resulted in a titer of 304 mg/L after 9 days of cultivation. Simulation with these 
parameters resulted in production of 197 kg within 3 months at a cost of 705 $/gram mAb. The 
breakdown of associated COGM costs is shown in Figure 4.5. Facility costs dominated COGM, 
followed by raw materials and labor.  
 
Figure 4.4. COGM break down for 304 mg/L process. 
Model consisted of 8x 25,000 L reactors operating on a 12 day cycle for 3 months of operation. The process 
modeled in SuperPro v7.0 software was a PEI-mediated TGE in CHO. 
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4.3.3 Scenario analysis  
After simulating a realistic process in a 200,000 L facility, scenario analysis was 
conducted with various capacity utilization structures and capital costs. As discussed above, the 
cost of the facility may range from $100-$1000M. In addition, the facility house equipment able 
to turn-over and generate multiple products within the same facility, or a multi-product facility. 
The multi-product facility, as oppose to a dedicated facility, could be run year round, and fixed 
costs could be distributed amongst all material produced. Because of these possibilities, the 
experimental model was simulated under various facility structures. These include either 3 
months of operation, which would be solely for bio-defense purposes, or a multi-use facility 
that operates for 12 months out of the year, where the remaining 9 months are used for other 
products production. 
 
 
Figure 4.5. COGM under different capital cost structures and utilization scenarios.  
Model consisted of 8x 25,000 L reactors operating on a 12 day cycle for 3 months of operation. The process 
modeled in SuperPro v7.0 software was a PEI-mediated TGE in CHO. 
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Simulation of the experimental process under various capital cost and utilization structures 
showed dramatic differences in the cost of antibody production (Figure 4.5). More expensive 
facilities produce antibodies at a higher cost. Similarly, dedicated facilities produce antibodies 
at a higher cost compared to a multi-product facility. The use of a multi-product facility, 
however, had a larger effect on the overall cost of production compared to the capital cost 
structure. These results suggest utilizing installed capacity through contract manufacturers who 
have multiple products in production, may be an optimal strategy for bio-defense purposes. 
 
4.4 Conclusion 
In this study, we aimed to assess the possibility of rapid, large scale production of monoclonal 
antibodies. A SuperPro model was constructed representing the most up to date methods in 
antibody production. The model was calibrated based off of published studies and parameters 
estimation was verified through lab scale experiments. The model predicted that a facility with 
200,000-L bioreactor capacity could produce between 32 and 1,274 kg of recombinant protein 
within 12 weeks of production. Production was highly dependent on process titer. Titer 
increases had marginal reductions in COGM above 500 mg/L. A scenario analysis of capital costs 
structures and utilization rates demonstrated a multi-product facility is an optimal strategy for 
bio-defense production. Future work to enable bio-defense capabilities of rapid monoclonal 
antibody production should focus on increasing titer and validating the assumptions that a TGE 
system will scale to 25,000-L bioreactors. In addition, this model was deterministic; a 
probabilistic one, which utilized a range of values for cost, process times and yields with an 
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associate probability density function for those values, would provide more realistic output 
estimates (Farid 2001; Farid et al. 2008a; Farid et al. 2008b).  
 
 
4.5 Appendix 
Detailed description of Unit operations and parameters 
A simplified deterministic model was created to simulate antibody production using TGE 
systems.  The process begins with a series of steps which cells are expanded using progressively 
larger vessels. Inoculum starts by thawing a tube of frozen cells and using it to inoculate a 500 
ml culture in a shaker flask. The culture is grown for forty two hours (2.3 doublings) then 
passaged into a disposable bioreactor at a 1:5 concentration split ratio. Similar growth and split 
ratios are carried on through two disposable bioreactors. There are four identical inoculum 
suites which are run in staggered mode to maximize throughput. These cultures are passaged 
into 1000-L stainless steel bioreactor and expanded to a 5000-L stainless steel bioreactor using 
growth times and split ratios described above. Contents from the 5,000-L reactor were 
concentrated using microfiltration and diafiltered using a 100 kDa MWCO hollow fiber at a 
shear rate of 20 L/m2 hr. Filtered culture were then feed into a 25,000-L stainless steel, stirred 
tank vessel. Transfection complexes consisting of appropriate amounts of DNA and PEI were 
prepared in an agitated vessel then transferred into the production bioreactor for transfection. 
250 g DNA and 500 g PEI were added per reactor, and assumed to be on hand, as subsequent 
analysis will show DNA fermentation and purification not to be rate limiting (Chapter 5). Post 
transfection production consists of ten days of a fed-batch operation with a bolus feed of 
20,000 L of production media four hours post transfection.  
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 Once fermentation is complete, the culture is pumped into a surge tank in order to free 
the bioreactor for turn-around. The culture is then passed through a stacked-disk centrifuge 
and filtered through a 0.45 µm dead-end filter into a storage tank. This recovery has a 95% 
yield. Passed filtrate is run through a Protein A affinity chromatography column. This step is 
carried out in four cycles at a loading capacity of 10 g/L and a 100 cm/min flow. The resin costs 
$7000.00 per liter, can be cycled forty times before having to be replaced, and has a binding 
capacity of 15 g/L. The overall yield of this step is 90%. 
 Elutant is filtered through a 0.45 µm dead-end filter into a storage tank then 
ultrafiltered to concentrate the filtrate 5 fold. There is a 5% denaturation rate associated with 
this operation. The retentate is then pumped into a tank containing a mixture of Tri-n-butyl 
phosphate (TNBP) and Polysorbate 80 (Tween 80), used to chemically inactivate any enveloped 
viruses found in the stream. This step has a 6% loss in product. The product is then filtered and 
loaded onto an anion exchange column, which has a 15 g/L capacity $1,600/L cost and a 200 
cm/min linear velocity. The elutant is mixed with ammonium sulfate and then passed over a 
hydrophobic interaction column (HIC). This column has a 40 g/L binding capacity and costs 
$3,200 per liter. Both resins can be cycled 40 times and have an aggregate yield of 90%.  
 As a final polishing step, the product is passed through a 0.1 µm viral exclusion filter. 
The filter can only be used once, and costs $27,000.  The product then undergoes a buffer 
exchange and concentration step using a difiltration unit followed by a final dead end sterile 
filtration. Five percent of the mAb is denatured during this step. Product is then held in a 
storage tank until needed. 
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CHAPTER 5. PLASMID DNA PRODUCTION FOR LARGE 
SCALE TRANSIENT GENE EXPRESSION  
 
Abstract 
Large scale production of recombinant proteins using transient gene expression requires large 
scale production of DNA plasmids. In order to evaluate the feasibility of such an approach, a 
process for very large-scale production of pDNA was designed based upon published literature.   
A resulting process was simulated and modeled using SuperPro designer 7.0 software.  Flow 
sheets were created and calibrated to experimentally-validated parameters. The model 
predicted that a 1000-L fermentor and associated purification equipment could produce 29.9 kg 
of pDNA in a year at a cost of $377/gram.  This amount of DNA would satisfy the pDNA 
requirements for large scale transient gene expression, in order to meet bio-defense needs. 
This capability would also be sufficient for production of pandemic pDNA vaccines or other 
clinical material. 
 
5.1 Introduction 
Demand for pharmaceutical grade plasmid DNA (pDNA) is expected to rise due to an increasing 
number of pDNA-products nearing completion of clinical trials as well as a surge of interest in 
transient gene expression methods (TGE; Geisse 2009; Lou and Saltzman 2000; Rozkov et al. 
2008). To satisfy this demand, especially markets where pDNA products will be injected into 
patients, economically feasible processes suited for manufacturing of gram to kilograms of 
purified pDNA per batch are needed. These production processes must meet regulatory 
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requirements from the authoritative bodies, such as the FDA, EMEA, and WHO (FDA 1996a; 
WHO 1998; Falk and Ball 2001; Smith 2001).  
 All polynucledotides are negatively charge under physiological conditions, extremely 
sensitive to enzymatic hydrolysis, and highly susceptible to size/shape dependent degradation 
by shear forces (Mairhofer and Grabherr 2008; Anchordoquy and Molina 2007). Plasmids are 
double-stranded, extra-chromosomal, circular polynucleotides, typically containing 3-20 kilo 
base pairs (bp), which corresponds to a relative molecular mass of 2*106 - 13*106 g/mol and a 
radius of gyration of 100nm and higher (Tyn and Gusek 1990). The supercoiled (sc) or covalently 
closed circular (ccc) topological pDNA isoform is the most desirable for therapeutic application, 
as it is considered the most stable (Sinden and Alkek 1994). Other forms are derived from the 
ccc form by either a single strand nick, resulting in a relaxed form, which is known as nicked or 
open circular (oc), or double strand nick resulting in linear DNA. Conjugation of plasmids leads 
to di-, oligo- and multimeric pDNA forms called concatemers and catenanes. (Summers 1996; 
Martin 1996).  For therapeutic application purity is often expressed as a percentage of ccc form 
compared to the total pDNA (US FDA 1996b). Under current regulations, direct human clinical 
use requires this ratio to be higher than 90% (US FDA 1996a; US FDA 1998).  Whether or not the 
DNA is intended for direct human clinical use, or as a process intermediate to make antibodies 
through TGE, impurities must be kept low, including a low content of genomic DNA (gDNA), 
RNA, proteins, and endotoxins (Weir 1999; Schleef 1999; Prazeres et al. 1999).  
 Beyond quality, there are economic aspects, such as yield, productivity and cost of 
goods that are vital for the success of an industrial manufacturing process. Elimination of 
bottleneck operations during the various phases is essential. Therefore simple, scalable 
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operations should only be considered as well as the avoidance of critical reagents such as 
animal derived compounds, detergents, and organic solvents. 
  Plasmids are generally transformed and synthesized in vivo 
by the bacterium Esherichia coli (E. coli; Prather-Jones et al. 2003). 
pDNA production processes typical begin with seed train operations 
which culminate in a production-scale fermentation step, which is 
followed by a sequence of downstream processing operations  
(Figure 5.1).  At the laboratory scale, production and purification of 
plasmids are generally viewed as relatively easy and simple 
procedures. However, plasmid production under laboratory 
conditions (non-optimized), generally leads to low volumetric titers 
(Prazeres 2011).  There has been increasing interest for larger, 
more productive processes which now routinely achieve 
productivity levels in the gram/liter scale (Varley et al. 1999; Diogo 
et al. 2001; Lander et al. 2002; Listner et al. 2006). Many of these 
advances have come from investigations into strain development 
(Bower et al. 2009; Cunningham et al. 2009), fermentation 
processes (Silva et al. 2009; Rozkov et al. 2006; Huber et al. 2005; 
Carnes et al. 2006; William et al. 2009b), purification strategies 
(Urthaler et al. 2005; Schmidt et al. 2003; Diogo et al. 2005) and 
economic scale-up (Hewitt and Nienow 2007; Onyeaka et al. 2003).   Many 
of these processes, however, utilize unit operations that either do not scale  
 
Figure 5.1. General 
plasmid DNA production 
process. 
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or will not meet appropriate regulatory guidelines. These include precipitation and extraction 
using organic solvents, RNA reduction using animal-derived RNase, and purification using 
density gradients or other means that employ toxic reagents such as CsCl, phenols or CsBr (Levy 
et al. 2000; Shamlou 2003;  Kahn  et al. 2000; Eon-Duval and Burke 2004). There have also been 
a number of economic and environmental impact analyses of pDNA production (Freitas et al. 
2006; Cliffe 2010; Hoare et al. 2005; Prazeres and Ferreira 2004), with some studies specifically 
addressing pDNA production for TGE (Wight 2001; Schmid et al. 2001; Rozkov et al. 2008; 
Cheng et al. 2011). Reported processes and their subsequent analyses, however, fail to provide 
meaningful predictions regarding current capabilities for two reasons. First, they do not take 
into account the most recent advances in pDNA production technology, and they do not 
address the market for large scale TGE. Therefore, the goal of this study is to estimate cost and 
time parameters involved in very-large-scale production of pDNA for transient transfection. 
  
 
5.2 Model case 
 The process utilized in this analysis was configured through a generalized upstream 
fermentation stage, and a detailed downstream purification stage. The unit operations are 
shown in Figure 5.1 and were modeled using SuperPro Designer Software version 7.0.  
 Fermentation processes were based off of an aggregate of current methods summarized 
in Table 5.1. Briefly, an inoculum preparation begins with thawing a tube of frozen E. coli cells. 
Cells are transformed with appropriate plasmid construct which contain the gene of interest, 
selectable marker, and origin of replication. The initial DNA construct would be chemically 
synthesized by traditional methods (Mullis and Faloona 2003; Stemmer et al. 1995). Bacteria 
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are expanded from shaker flasks to a 10-L working volume stainless steel reactor. Cell mass is 
cultivated until sufficient quantity is generated. Culture is transferred to a 1000-L stainless steel 
fermentation vessel where fermentation is carried out. Plasmid production is induced through 
the addition of supplements and the use of temperature shifts (Williams et al. 2009b). The final 
cell concentration or Dry Cell Weight (DCW) and the specific yield of the production fermentor 
are critical output from this set of unit operations. The culture is then stored in a surge tank and 
purification begins.  
 The downstream operations, or purification of plasmid DNA, were based off of an 
industrial scale process developed by Urthaler et al. (2005). The process is generic and scalable 
and has been used to purify pDNA from 200 to 4000-L fermentations (Urthaler et al. 2005). The 
process fulfills regulatory requirements and delivers pharmaceutical-grade pDNA, which is up to 
98% ccc. The final genomic DNA content is lower than 10 µg/mg plasmid DNA and endotoxin 
content lower than 0.1 EU/mg plasmid DNA. The process described here utilized a 1000-L 
fermentation tank and equipment sized to handle purification of subsequent material 
accordingly.  
 The entire flow sheet for pDNA production is shown in Figure 5.2. The process consists 
of inoculum preparation, seed train expansion, production scale fermentation, primary 
recovery, gentle lysis and clarification, conditioning, three chromatographic steps, and a final 
filtration/ formulation step, as listed in the generalized process (Figure 5.1). 
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Figure 5.2. Plasmid production and purification flow sheet. 
Fed-batch, temperature induced plasmid production with E. coli in 1000-L stirred tank fermentors was modeled 
using SuperPro Designer v7.  
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5.3 Model calibration 
 In order to calibrate the base-case to fit realistic material flows, an overview of high-
titer plasmid fermentation processes was prepared and examined (Table 5.1). Four 
fermentation output parameters were compared among key references.  For the base-case 
scenario, the averages of these output parameters were used.  These fermentations rely on 
nutrient-limited, fed-batch processes with plasmid induction systems to achieve high titers. The 
use of multiple sources and averaging their values provides a better estimate how current 
technology would apply to a new manufacturing organization. Some of the key parameters 
involved were the final cell density, measured either by an optical density (OD as measured at 
600 nm) and/or a dry-cell weight (DCW), the final volumetric productivity, and the specific 
yield.  When not specified in the reference, a final DCW was calculated from the published OD 
and the common ratio of 0.4 g/L DCW per 1 unit OD (Pranther et al. 2003).  The average final 
DCW used in the base-case model was 42.7 g/L and the average plasmid yield was 37.8 mg 
pDNA/ g DCW.  
Table 5.1. Fermentation overview 
Final Cell OD  
Final Volumetric 
Productivity 
(mg/L) 
Final dry-cell 
weight (g/l)* 
pDNA yield                 
(mg/g dry cell 
weight) 
Reference 
90 1600 36 39 Listner et al. 2006 
88 2200 35.2 62.5 Carnes et al. 2010 
115 2590 46 56.30 Carnes et al. 2010 
84 1210 33.6 36.01 Williams et al. 2009a 
97 1070 38.8 27.58 Carnes et al. 2006 
86 595 34.4 17.30 Singer et al. 2009 
187 1923 74.8 25.71 Phue et al. 2008 
106.7 ± 36.9 1598 ± 694 42.7 ± 14.8 37.8 ± 16.5 
Average  ± standard 
deviation 
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  *Cell density was estimated based on an OD600 of 1 being equivalent to 0.4 g/l DCW. 
 
 Calibration of downstream material flows were based off of the detailed work by 
Urthaler et al. (2005), who rigorously characterized this purification regime. The overall yield of 
the process is 65% and provides 96% pure plasmid DNA at a final concentration of 3.3 mg 
pDNA/ml in a Tris-EDTA buffer  (TE) (Table 5.2).   
Table 5.2. Downstream key assumptions  
 
Adapted from Urthaler et al. 2005 
 
 
 Other key assumptions involved in model development were an uptime of 90 days per 
year with a capacity utilization of 95%, 1000-L production fermentor, and a 5% process failure 
rate (Table 5.3). Greater detail for each unit operation can be found in the Appendix.  
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Table 5.3. Base-case assumptions  
Production System E. coli in stirred tank fermentor 
Product High copy number, codon optimized plasmid DNA 
Working volume of pDNA production 
bioreactor 
1,000 L 
Upstream 2 day fermentation, 12 hour harvest, 1 day turn-around 
Biomass Yield 42.7 g/L DCW 
pDNA Yield 37.8 mg/g DCW 
Annual plant up-time 90 days 
Final Product Configuration 3.3 mg/ml pDNA in TE Buffer  
Downstream Process Yield 65% 
Process Failure Rate 5% 
 
 
 
 
5.3 Results 
5.3.1 Economic overview 
 Table 5.4 shows the key economic evaluation parameters. For a plant of this capacity, 
the total capital investment is around $17.6 million. The plant would be capable of producing 
29.9 kg of pDNA within 3 months at a cost of goods manufactured (COGM) of $377/ gram. This 
COGM compares to other studies (Freitas et al. 2006) which found a unit cost near $500/ gram 
pDNA for 23.2 Kg produced/year. Cost differences between these studies were due to greater 
scale of economies from both larger equipment and batch sizes, higher efficiencies in unit 
operations and shorter batch times.  
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Table 5.4. Economic results overview 
Total Capital Investment $17,600,000 
Operating Cost $11,300,000 / 3 months 
Production Rate 29,900 g / 3 months 
Unit Production Cost $ 377/gram 
 
 
 The total equipment cost was estimated to be $18.6 million, which includes a 20% 
buffer for unlisted equipment, such as inoculum preparation supplies. For a full list of 
equipment and consumable requirements, see Appendix Table 5.1 and 5.2 representatively. A 
breakdown of COGM is shown in Figure 5.3. The primary cost driver is Facilities (43%) followed 
by labor (20%) consumables (17%) and raw materials (11%). Laboratory QA/QC costs were low 
(>5%). QA/QC costs were calculated as a linear function of labor, which may not include all 
relevant QA/QC costs involved. A more detailed investigation was out of scope for this study 
due to the complexities of regulatory and firm specific quality costs. 
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Figure 5.3. Cost break down per gram of pDNA.  
 
 
5.3.2 Capacity planning for pDNA production 
 In order to determine the appropriate size production facility, production equipment 
was calculated based on requirements from TGE cell culture. Figure 5.4 shows the process flow 
diagram for TGE. Purified pDNA plasmid, produced in the E. coli plant, is used to transfect CHO 
cells in a cell culture facility. To determine the amount of pDNA needed for cell culture 
transfections, the following assumptions were made: 
 The harvest volume from each of the cell culture bioreactor is 25,000 liters. There are 
assumed 8 bioreactors for a total cell culture capacity of 200,000 L. Cycle times for cell culture 
bioreactors is 12 days. Therefore a tank is ready for transfection every 1.5 days, or 4-5 batches 
per week. Each 25,000 L bioreactor requires 250 grams per run. A conservative target 
production rate for purified pDNA form E. coli is between 1 and 2 kg per week, or 12- 24 kg for 
the three month window of operation.  
 Complete utilization of the plant generates over 29.9 Kg of pDNA per year. Each batch of 
pDNA from the 1000-L process generates 1.15 kg of material. The first batch of pDNA material 
is released in 140 hours, and a new batch is released every 74 hours thereafter (Figure 5.5). A 
smaller sized fermentor, possibly 500-L, may be able to fulfill the low end needs of a cell culture 
transfection, but both industry’s experience with and installed capacity of 1000-L scale 
fermentors support the use of the larger size vessel.   
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Figure 5.4. General process diagram for TGE.  
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Figure 5.5. Project timeline for multiple pDNA production batches.  
 
 
 
5.3.3 Sensitivity analysis regarding pDNA production 
 Due to the inherent variability of biological processes, it was necessary to investigate 
the multiple scenarios where the pDNA production process may not work as expected. Four 
critical areas were identified as major points of variability. Biomass generation, pDNA specific 
yield, primary recovery, and purification were investigated for their effects on the pDNA 
production process. The yield or productivity of each area was decreased by 5, 15 or 45% and 
the output effects on COGM and annual yield were observed compared to the base-case 
(Figure 5.6). Small changes in any parameter did not affect the overall process in terms of 
COGM or pDNA production. However, larger changes in operations resulted in a much less 
121 
 
productive process. There was a trend that the closer the unit operation is to the final drug 
substance, the more dramatic the effect on the entire process (i.e. Purification> Recovery> 
Specific Yield > Biomass). As the concentration of the final product was more concentrated in 
each successive step, the dramatic effects observed in downstream operations were expected. 
 
 
 
 
Figure 5.6. Sensitivity analysis on pDNA production processes.  
Each unit operation in a scenario was decreased by 5% (blue), 15% (red) or 45%  (green) then productivity 
(kg/year) and COGS ($/gram) were compared against the base-case model.  
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5.4 Conclusion 
 In this study, we aimed to assess the potential of large scale plasmid production. A 
SuperPro model was constructed representing the most up to date methods in plasmid 
production. The model predicted that a 1000-L fermentor and associated purification 
equipment could produce over 29.9 kg of pDNA in a year at a cost of $377/gram.  This amount 
of DNA would satisfy the pDNA requirements for large scale TGE, or for use in pandemic pDNA 
vaccines. Bio-defense interest groups could purchase and operate such a facility, or capacity 
could be purchased as needed in the event of a mass casualty event. While these results are 
based off of published studies, there may be a number of problems associated with 
implementing this process. Freedom to operate is a significant concern, as many aspects of the 
process technology are patented (Carnes and William 2007; Bulter et al. 2001; Thatcher et al. 
1999; Schmidt et al. 2003; Kristyanne et al. 2003; Huber et al. 2005). In addition, this model was 
calibrated off of studies that utilize model systems with fully optimized plasmids and host 
organisms. These studies have benefited from a plethora of process development, and, as often 
is the case in the literature, only the best results are shown. Learning costs associated with 
achieving manufacturing success may be significant. Moreover, there is significant plasmid 
specific variability. Molecular biology approaches, such as origin of replication, codon 
optimization, and size matching, may provide methods to reduce this variability; however, 
plasmid production differences have been observed (Prazeres 2011). Last, this model was 
deterministic with single values for parameters; a probabilistic one with a statistical range of 
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values would provide more realistic material flow estimates (Farid 2007; Farid et al. 2005a; 
Farid et al. 2005b) 
 
 
5.5 Appendix  
5.5.1 Unit operation details 
5.5.1.1 Inoculum preparation 
Inoculum preparation begins with thawing a tube of frozen E. coli cells, typically DH1, DH5α, or 
K12. Cells are transformed with appropriate plasmid construct harboring a selectable marker 
(P1). Initial DNA construct is assumed to be ready on hand (~1 µg), which is assumed to be 
chemically synthesized by traditional methods (Mullis and Faloona 2003; Stemmer et al. 1995). 
Bacteria are expanded using simple seed train medium to achieve progressively larger 
fermentation volumes. Transformation operations and expansion up to 1-L culture volumes 
take 20 hours in total. 
 1-L inoculum is transferred to a 10-L working volume stainless steel reactor (P-3). 
Disposable bioreactors have been investigated for microbial fermentations (Galliher 2008; 
Gaugler et al. 2002; Oosterhuis and van den Berg 2011); however heat and oxygen limitations 
exist on current disposable configurations. Stainless steel bioreactors are therefore 
implemented. Simple media is used for this expansion step. Total time for this operation is 24 
hours.  
 Fermentation is carried out using fed-catch protocols. Seed train is diluted 100x with 
prepared fermentation media in a 1000-L stainless steel fermentation vessel (P-1). Aerobic 
cultivation of the cells is sustained at all times by adjusting airflow (P-35), agitation rate, and 
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back pressure in the reactor. Temperature is maintained at 37°C and pH at 7.1±0.1 by addition 
of ammonium hydroxide. After sufficient biomass accumulation, temperature is shifted to 42°C. 
Growth continues for one additional doubling with the addition of supplemented fed-batch 
media. The total time for this operation is 48 hours, with 40 hours of growth and 8 of post-
temperature induction. Final concentration of cells in the fermentor is 43 g/L (dry cell weight, 
DCW). At the end of fermentation, the broth is transferred to a storage vessel (P-36). Seed train 
and production vessel are both cleaned and sanitized with high pressure steam in order to 
prepare for the next batch lasting 24 hours. 
 
5.5.1.2 Recovery 
 
 Cells are harvested in a disk stack centrifuge (P-2) with 95% recovery over 12 hours. The 
broth is concentrated 20 fold from 1000-L to 50-L. Subsequent lysis of E. coli cells are carried 
out using a modified version of previously reported methods (Ciccolini et al. 2002; Meacle et al.  
2004; Clemson and Kelly 2010). Modifications to this step are especially important due to the 
potential for pDNA damage from caustic solvents and shear stresses (Lengsfeld and 
Anchordoquy 2001; Freitas et al. 2007). Briefly, the cell pellet is resuspended to 150 g/L cell in 
resuspension buffer (50 mM Tris-HCl, 10 mM EDTA, pH 8.0). The mixture is blended in a tank (P-
5) until a homogenous suspension is obtained, roughly 30 minutes. Subsequent lysis is achieved 
by one part resuspended pellet, and two parts 150 mM NaOH with 1% SDS solution. This 
solution is mixed with 100 rpm gentle orbital agitation for 10 minutes. The mixture is then 
neutralized with one part 3 M potassium acetate pH 5.5. Clarified lysate is collected in a surge 
tank (P-7), then concentrated using microfiltration on a 100 kDa MWCO hallow fiber membrane 
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(P-6) with a shear rate of 20 L/m2 *hr. During this process there is a 5% degradation rate of 
intact pDNA where there is a 7 fold concentration of the solution.  Once lysate is concentrate, 
addition of ammonium sulfate prepares the solution for binding pDNA on the HIC-column. A 
stock solution of 4 M ammonium sulfate is used to condition the concentrated lysate, as high 
concentrations of the salt can precipitate pDNA out of solution and reduce recovery. At this 
concentration, only proteins and gDNA impurities form aggregates and precipitate out of 
solution. These particulates are filtered out using dead end filtration (P-8) prior to loading the 
HIC-column. A 4.5 µm filter is used to remove large particles from entering the HIC-column. 
Membranes with smaller pores result in loss of pDNA and filter fouling.  Capacity of the filter 
was assumed to be 100 L/m2. The overall conditioning steps lead to 83% yield with a 95% 
recovery.  
 
5.5.1.3 Purification 
 This section achieves two objectives: to concentrate pDNA and to remove a large 
portion of impurities.  Purification is achieved through the use of three different 
chromatography steps, each of which employ different separation principles for isolation.  
 The initial column is a HIC membrane (P-10). Maximal dynamic binding capacity (DBC) 
for pDNA at a linear velocity of 120 cm/h is around 2 g pDNA/L. This was determined using 
breakthrough curves.  A pDNA recovery of more than 95%, not including regeneration fractions 
are typical. Yield was set at 87% with a 5% pDNA degradation rate.  
 As the second chromatography step, AIEC is utilized due to a higher yield with pre-
purified pDNA solutions compared to other processing steps. Because this process can serve as 
a concentration step, weak AIEC-CIM adsorbents with a DBC between 5 and 10 g pDNA/L is 
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used (P-27). Loading and wash steps use high linear flow rates, while elution uses a reduced 
flow rate with a step wise increases in conductivity. This step had a yield greater than 90% and 
nearly 10 fold concentration.  
 The order of column purification was optimized from other protocols, which often start 
with Anionic exchange chromatography (Cunningham 2009; Varley et al. 1999). These protocols 
often have lower yields and recoveries, especially if lysate is not conditioned or loading time is 
delayed due to long cycle times and blocking of the membrane during AIEC operations (Urhaler 
et al. 2005). High salt concentrations in conditioned lysate may lead to a more stable solution 
compared to one that has been daifiltered against a AIEC loading buffer. 
 The final purification step uses size exclusion chromatography (P-18), which allows for 
further impurity removal and buffer exchange. A sepharose support with a maximum feed 
volume of 35% CV at a velocity of 60 cm/h. Direct loading of the AIEC elution is carried out. 
Elution buffer is the final buffer desired in formulation (50 mM Tris-HCl, 10 mM EDTA, pH 8.0).  
Yield for this step is greater than 95%.  
 
5.5.1.4 Formulation 
 For a higher pDNA concentration in drug substance, concentration by tangential flow 
filtration is used (P-9). 100kDa membranes result in yields great than 90% depending on the 
desired final concentration are achieved. Shear rates of 80 L/ m2 * hr are use to concentrate up 
to 10 fold.  
 Final polishing filtration is a simple 0.22 µm depth filter to ensure sterility. Capacity of 
the filter has been determined to be 100 L/m2 with flow rates up to 5 L/ m2* min. Yields of 95-
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100% are achieved.  Bulk pDNA drug substance is housed in a surge tank before freezing and 
transport to the cell culture transfection facility.  
 
5.5.2 Additional results 
Table a5.1. Equipment overview   
Name Size (L, M2, or L/hr) Purchase/Installation Cost 
Shake Flask Rack 1.5 15 
Fermentor 1,256.35 2,500,000 
Seed Reactor 127.21 2,223,000 
Blending Tank 1,000 1,077,000 
Disk-Stack Centrifuge 21,306.02 148,000 
Clarification Tank  2,555.38 4,143,000 
Blending Tank 2,242.82 402,000 
HIC Column 187.06 732,000 
AIEC Column 65.1 519,000 
SEC Column 524.1 1,749,000 
Blending Tank 3693.77 431,000 
Dead-End Filter 4.59 47,000 
Heat Sterilizer 900 219,000 
Air Filter 30,152.32 7,000 
Flat Bottom Tank 1,114.73 177,000 
Microfilter 28.84 137,000 
Dead-End Filter 1.2 23,000 
Daifilter 71.07 242,000 
Receiver Tank 333.55 94,000 
 
Table a5.2. Consumable overview   
Consumable Unit Cost     Annual Amount 
  $/ (item, M2 or L)   
500 ml Shake Flask 1.7 858 
0.2 µm Diafilter 1,000 286 
0.1 µm Polishing Filter 400 82 
4 µm Dead-End Filter 15 343 
HIC Resin 1,500 5,350 
AIEC Resin 2,000 1,862 
Gel Filtration Resin 800 11,242 
100 kDa MWCO Hollow 
Fiber membrane 
800 825 
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CONCLUSION AND FUTURE WORK 
 
 The goal of this thesis was to investigate both the technical and operational feasibility of 
scaling transient gene expression to large scale for the production of full-length, human-like 
glycosylated antibodies as medical countermeasures for biological catastrophe.  Operational 
simulations predicted that a 1,000-L fermentor would produce sufficient plasmid DNA at a cost 
of approximately $377/gram (Chapter 5). This DNA could be utilized in a 200,000-L bioreactor 
facility produce between 32 and 1,274 kg of recombinant antibody within 3 months of 
operation. Simulation with experimentally validated parameters in the same facility resulted in 
production of 197 kg within 3 months at a cost of 705 $/gram mAb (Chapter 4). These 
simulations predict that large-scale transient gene expression can provide sufficient lifesaving 
countermeasures if titer improvements are possible and can scale to 25,000-L bioreactors. 
Experimental transfections identified optimal cell/DNA/PEI ratio, transfection incubation time, 
temperature, and agitation set points which could be scaled to very large bioreactors. Through 
this process characterization, a method was developed using scalable cross flow filtration which 
achieved the highest reported titer in CHO TGE (Chapter 3). In addition a phenomenological 
mass transport model was developed to investigate potential mass transfer limitations upon 
scale-up. This model identified methods that could guide selection of scale-up regimes (Chapter 
2).  
 Ultimately, this work has predicted the possibility of achieving large scale transfections. 
Future work could include pilot scale studies to validate the findings from this thesis and further 
develop capabilities for rapid production of very large quantities of recombinant protein. Other, 
less costly efforts could be directed at further developing process understanding of TGE. 
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Specifically, understanding agitation’s effect on polyplex formation and stability in cell culture 
media would provide needed insight into the mass-transport limitations of TGE. This could take 
the form of a correction factor for the mass-transport model which could provide additional 
predictive capability and determine if polyplex degradation plays a role in determining the mass 
transfer requirements.  Moreover, investigating transfected cell’s shear sensitivity may indicate 
additional factors to consider when developing TGE compatible bioreactors.  
 Other efforts could be directed at optimizing TGE in CHO with molecular biology 
methods. This could include strain engineering of anti-apoptosis cell lines and introducing 
episomal replication machinery.  Such efforts may involve partnering with other research 
groups or firms who have already made advances in these areas.  Moreover, developing 
nuclear-tags on polyplexes and enhance intra-cellular transport may ultimately provide the best 
gains in TGE performance.   
 Last, development of process simulation models for TGE in disposable bioreactors may 
be invaluable. While large scale fixed capacity is available, the use of such facilities will require 
complex contracts involving a host of stake-holders. Development of optimal single use 
technologies for TGE would provide an alternative, complimentary path to help mitigate the 
impact of a biological catastrophe.  
 
